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ABSTRACT 
Prostate cancer is the most commonly diagnosed cancer among men in the United 
States. Despite improvements in screening, diagnostic methods, and treatment, African-
American men have an increased risk of total and aggressive prostate cancer. In recent 
years, a growing body of evidence linking biomarkers of calcium and parathyroid 
hormone (PTH) to prostate cancer development has emerged. Circulating calcium, 
phosphorus, and PTH are homeostatically related. Prior studies linking prostate cancer 
and circulating calcium and PTH have produced inconclusive results, and no studies have 
examined the association between serum phosphorus and prostate cancer. The present 
study examined the relationship between circulating calcium, phosphorus, and PTH and 
aggressive prostate cancer in a sample of African-American and European American men 
in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Serum calcium was 
associated with a modest decreased odds of aggressive prostate cancer though the 
confidence interval lacked precision. There was suggestion of effect modification by 
overweight/obesity status, though these results were not statistically significant. High 
serum phosphorus was associated with an increased odds of aggressive prostate cancer 
across various categorization approaches. There was a slight inverse association between 
aggressive prostate cancer and PTH, and this association was modified by number of 
comorbidities. The joint effects of circulating calcium, phosphorus, PTH, and 25(OH)D 
were observed. Across categories of low and high analytes, serum phosphorus was 
associated with increased odds of aggressive prostate cancer. Higher serum phosphorus 
 v 
may reflect high dietary intake of phosphorus and a less healthy diet overall. A previous 
study found a positive association between higher dietary phosphorus intake and 
aggressive prostate cancer risk, corroborating our results. Future studies are warranted to 
more thoroughly examine the role of serum phosphorus in prostate cancer progression.  
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CHAPTER 1 
INTRODUCTION 
1. Statement of the problem 
General 
Prostate cancer is the second most common cancer diagnosed in men globally, 
following lung cancer (Bray et al., 2018). In 2018, there were 1,276,106 new prostate 
cancer diagnoses and 3.8% of cancer deaths were due to prostate cancer (Bray et al., 
2018).  In the United States, prostate cancer is a leading cause of malignancy among men 
(Siegel et al., 2019). An estimated 191,930 new cases of prostate cancer will be 
diagnosed in 2020 and 1 in every 9 men are expected to develop invasive disease in their 
lifetime (Siegel et al., 2020). The mortality rate for prostate cancer has declined by 53% 
within the past two decades (Siegel et al., 2018), which could be attributed to advances in 
early detection and treatment of prostate cancer (Kelly et al., 2017). Recent trends show 
that prostate cancer was the leading cause of death among men 80 years and older and the 
third leading cause of death among men 60 to 79 years (Siegel et al., 2019). Between 
2010 and 2014, the incidence rates of prostate cancer were 107.0 (per 100,000) among 
European-American (EA) men, 186.8 (per 100,000) among African-American (AA) men, 
58.4 (per 100,000) among Asians/Pacific Islanders, 78.3 (per 100,000) among American 
Indian/Alaskan Natives, and 97.0 (per 100,000) among Hispanic men (Siegel et al., 
2018).  
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Risk Factors  
 Age and family history are established risk factors for prostate cancer (Grossman 
et al., 2018).  In addition, certain racial/ethnic groups are at increased risk of prostate 
cancer incidence and mortality. For decades, AA men have had substantially higher 
incidence rates of prostate cancer compared to EA men (Odedina et al., 2009). After 55, 
the risk of prostate cancer substantially increases and peaks between the ages of 70-74 
(Gann, 2002). Men with a family history of prostate cancer are 2-3 times as likely to 
develop prostate cancer as compared to men with no family history of prostate cancer and 
the risk tends to be stronger with increasing number of family members with prostate 
cancer (Kicinski et al., 2011). Emerging evidence from epidemiologic studies suggests 
that modifiable risk factors like obesity and smoking appear to increase risk of prostate 
cancer incidence, progression, and mortality, but results are only suggestive (Kenfield et 
al., 2011; Huncharek et al., 2011; Vidal et al., 2014; Lavalette et al., 2018).   
Screening   
There are two common screening methods for prostate cancer: digital rectal exam 
(DRE) and prostate specific antigen (PSA). The DRE is a method by which a physician 
inserts a finger into the rectum to examine the prostate for abnormalities. Prior to the 
introduction of PSA, which measures the level of PSA in the blood, the DRE was the 
only screening tool for prostate cancer. Between the late 1980s and early 1990s, the 
incidence of prostate cancer surged by 82% and a contribution to this trend is the 
introduction of the PSA screening test (Potosky et al., 1995). Approximately 60% of the 
prostate cancers detected by PSA screening are overdiagnoses, which means the disease 
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would not become clinically significant (Sandhu & Andriole, 2012; Welch & Black, 
2009).  
Due to issues with overdiagnosis and overtreatment in prostate cancer cases that 
would otherwise remain asymptomatic, the United States Preventive Services Task Force 
(USPSTF) recommended against routine prostate cancer screening among men of all ages 
in 2012 (Moyer et al., 2012). Following these recommendations, the frequency of PSA 
screening and prostate cancer incidence declined (Fleshner et al., Howard et al., 2013; 
Patel et al.,2018). Concerns about a decline in PSA testing and prostate cancer incidence 
being misinterpreted and masking increased rates of aggressive prostate cancer arose, 
specifically among high risk men (Negoita et al., 2018; Ahlering et al., 2019). In an 
update in 2018, the USPSTF suggested that the decision to undergo PSA screening in 
men ages 55-69 be at the discretion of the patient and physician, but the recommendation 
against screening for men over the age of 70 remained unchanged (Grossman et al., 
2018). 
Treatment and Survival  
 The primary benefits of prostate cancer screening are early detection and 
treatment, resulting in more favorable outcomes. Presently, three commonly utilized 
treatments for localized prostate cancer exist: radical prostatectomy, radiation therapy, 
and active surveillance (Grosseman et al., 2018). The 10-year survival rate for localized 
prostate cancer, regardless of treatment type, is estimated to be 99% (Hamdy et al., 
2016). For men with advanced prostate cancer, treatment includes hormonal therapy, 
radiation, chemotherapy, immunotherapy, and bone targeted therapy, and new treatments 
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are evolving. Despite the treatments available, the 5-year survival rate for 
advanced/metastatic prostate cancer is approximately 30% (Siegel et al., 2019).   
Prostate Cancer in North Carolina and Louisiana  
 In 2020, there will be an estimated 2,970 and 7,200 incident cases of prostate 
cancer in Louisiana and North Carolina, respectively (Siegel et al., 2020). Moreover, 
approximately 450 and 1,010 men in Louisiana and North Carolina, respectively, are 
expected to die from the disease (Siegel et al., 2020). The prostate cancer mortality rates 
in North Carolina (19.9 per 100,000) and Louisiana (20.8 per 100,000) are higher than 
the national rate (19.1 per 100,000) (Siegel et al., 2020). The incidence rate of prostate 
cancer among AA men in Louisiana (192 cases per 100,000) is higher than the incidence 
rate among AAs nationally (179 per 100,000) and in North Carolina (183 cases per 
100,000) (DeSantis et al., 2019).  Furthermore, the prostate cancer specific mortality rates 
in the US (39.8 per 100,000) and North Carolina (39.6 per 100,000) among AA are 
slightly higher than that of Louisiana (37.0 per 100,000) (Desantis et al., 2019).   
Racial Disparities   
On average, AA men are diagnosed with prostate cancer at a younger age (66 
years) than EA (69 years) (Howlader et al., 2018). Between 2011 and 2015, the incidence 
rate of prostate cancer for AA men was approximately 76% higher than that of EA 
(Desantis et al., 2019).  AA men tend to present with more aggressive and advanced stage 
disease at diagnosis (Powell et al., 2010, Tsodikov et al., 2017; Pietro et al., 2016). 
Although the prostate cancer mortality rate among men of all races has declined in the 
last 20 years (Desantis et al., 2019), racial disparities in mortality rates among AA persist. 
Between 2011 and 2016, the age adjusted mortality rate for AA (179.2 per 100,000) was 
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significantly higher than that of EA (101.7 per 100,000) (Siegel et al., 2019). The lifetime 
probability of AA men dying from invasive prostate cancer has recently been reported to 
be 4%, which is nearly double that of EA men (2.2%) (Desantis et al., 2019). Moreover, 
studies have found that AA had significantly higher serum PSA levels than EA men, 
irrespective of demographic and cancer- specific characteristics (Mavropoulos et al., 
2007; Leapman et al., 2016). The associations between risk factors that appear to increase 
risk of prostate cancer and poorer outcomes tend to be more pronounced among AA men 
(Murphy et al., 2013; Barrington et al., 2015).  
Socioeconomic status (SES) influences frequency of screening, access to adequate 
care, preventive health services, and health behaviors (Pampel et al., 2010; Singh & 
Jemal., 2017). Socioeconomic factors that differentially impact AA contribute, at least 
partially, to the racial disparities observed in prostate cancer outcomes (O’keefe et al., 
2015; Taksler et al., 2012).  Evidence shows that there is a link between SES and prostate 
cancer mortality, but among AA men the association is stronger than that of EA men 
(Siegel et al., 2019; Albano et al., 2007; Jemal et al., 2005).  Moreover, in a study of low 
risk prostate cancer patients, after adjusting for socioeconomic parameters and 
clinicopathological features, AA race was the only predictor of treatment (Albern et al., 
2013). 
Alongside social factors, genetic and biological characteristics among tumors of 
AA men with prostate cancer are substantially different than those of EA and could have 
implications for the disparities in prostate cancer outcomes observed (Aizer et al., 2014).  
Genetic mutations and biomarkers associated with aggressive prostate cancer tend to be 
overexpressed or more prevalent in AA men as compared to EA men (Khani et al., 2014; 
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Kim et al., 2011; Kwabi-Addo et al., 2010). Several studies suggest that AA men are 
more likely to present with higher Gleason grade tumors at diagnosis as compared to EA 
men (Powell et al., 2010; Iremashvili et al., 2012). 
Calcium, Phosphorus, Parathyroid Hormone (PTH) and Prostate Cancer  
Various studies have examined the role of dietary calcium and prostate cancer 
outcomes but have produced inconsistent results. Several studies have reported that high 
intakes of dietary calcium are associated with an increased risk of prostate cancer (Mitrou 
et al., 2007; Kesse et al., 2005) and aggressive disease (Batai et al., 2017; Wilson et al., 
2015), but other studies report no association with prostate cancer and/or progression 
(Tavani et al., 2005; Chan et al., 2000). Research examining the association between 
prostate cancer and phosphorus intake is not well-studied, and existing studies have 
produced inconclusive findings. Results from a prospective cohort study on the 
association between calcium and phosphorus intake and prostate cancer suggest that high 
phosphorus intake is independently associated with an increase in total, lethal, and 
aggressive prostate cancer risk (Wilson et al., 2015), whereas other studies produced null 
results (Chan et al., 2000; Tavani et al., 2005).   
Both phosphorus and calcium are found in similar food sources, with phosphorus 
being more widely distributed in the food supply than calcium. Serum calcium is under 
tight homeostatic control and therefore, not a biomarker of dietary calcium. Because of 
the wide distribution of phosphorus in food sources, it is hypothesized that dietary 
assessments underestimate phosphorus intake. This could contribute to the inconclusive 
findings on the accuracy of serum phosphorus as a marker of dietary phosphorus (Moore 
et al., 2015; Uribarri & Calvo, 2014; Calvo et al., 2014).  
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Under normal homeostatic conditions, serum parathyroid (PTH) is primarily 
responsible for maintaining calcium and phosphorus homeostasis. As serum calcium 
decreases, PTH is stimulated and produces the active form of vitamin D (1,25(OH)2D), 
which works to increase serum calcium concentration (Goltzman et al., 2018). When 
serum calcium is elevated, PTH secretion is reduced (Goltzman et al., 2018). Conversely, 
increases in serum phosphorus stimulate PTH secretion (Vorland et al., 2017). In addition 
to effects on 1,25(OH)2D levels, PTH indirectly stimulates production of fibroblast 
growth factor 23 (FGF-23), a hormone that functions primarily to reduce serum 
phosphate levels (Vorland et al., 2017). 
 Results from in vitro studies suggest that PTH related protein (PTHrP) is a 
mediator in the development of prostate cancer and metastases in bone (Laio et al., 2008). 
In a study conducted by Aydin et al. (2014), PTH and PSA were positively correlated 
among men with and without prostate cancer. Furthermore, calcium sensing receptors 
(CaSRs) are present on both normal and cancerous prostate cancer cells, and these 
receptors are expressed at higher levels in metastatic prostate cancer tissues derived from 
bone (Feng et al., 2014). The homeostatic mechanisms behind serum calcium, serum 
phosphorus, and PTH are quite complex and evidence on the associations between these 
variables and prostate cancer outcomes is either limited or has produced mixed findings 
as described in more detail in Chapter 2. 
Specific Aims  
The purpose of this study was to examine the association between circulating 
calcium, phosphorus, and PTH and aggressive prostate cancer. The Specific Aims were 
as follows: 
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1. To evaluate the associations between circulating calcium, phosphorus, PTH 
and prostate cancer aggressiveness independently. We hypothesized that 
circulating calcium, phosphorus, and PTH would be positively associated with 
aggressive prostate cancer. 
2. To examine the joint associations of circulating calcium, phosphorus and 
PTH. To compare our results with previous studies, we included plasma 
vitamin D in the joint analyses; the main effects of plasma vitamin D 
metabolites have already been published in our dataset (Steck et al., 2015; 
Ramakrishnan et al., 2019).  
3. To examine whether associations between circulating calcium, phosphorus, 
and PTH and aggressive prostate cancer are modified by body mass index 
(BMI), comorbidities, or smoking status.  
Significance of Research  
Prostate cancer is the leading cause of malignancy among men in the United 
States (Siegel et al., 2019).  Only three factors have been consistently associated with risk 
of prostate cancer: age, race/ethnicity, and family history. In recent years, a growing body 
of evidence linking biomarkers, lifestyle, and sociodemographic factors to prostate cancer 
development and progression has emerged. To date, several studies have examined the 
association between serum calcium and prostate cancer (Salem et al., 2013; Schwartz & 
Skinner, 2012; Van Hemelrijck et al., 2012; Jackson et al., 2015; Skinner & Schwartz, 
2008; Halthur et al., 2009). The findings from these studies are inconsistent, as some 
report no significant increase in risk and others report inverse and positive associations. 
Furthermore, one study evaluated the impact of PTH and serum calcium on prostate 
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cancer risk (Brandstedt et al., 2016). In the main effects model, no statistically significant 
associations were observed between circulating calcium or PTH and risk of prostate 
cancer. However, positive and negative associations were observed within strata of 
calcium and PTH.  
 Current literature is limited by small sample size, lack of information on 
tumor stage/grade, insufficient covariates, and/or racial homogeneity. No studies have 
assessed the association between serum phosphorus and prostate cancer outcomes. 
Calcium, phosphorus, and PTH are homeostatically related, but to our knowledge, no 
studies have evaluated their independent and/or joint effects in relation to prostate cancer 
aggressiveness. This study examined the independent effects of circulating calcium, 
phosphorus, and PTH, along with their joint effects, on prostate cancer aggressiveness in 
a representative sample of EA and AA men. 
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CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
1. Primary Hypothesis – Circulating Calcium, Phosphorus, PTH and Prostate 
Cancer  
 There is biologic plausibility for a role of calcium, phosphorus and PTH in 
prostate cancer development and progression. In this section, we describe the potential 
biologic mechanisms and summarize the epidemiologic studies that have examined 
associations between calcium, phosphorus, and PTH and prostate cancer in humans 
(Table 2.1). 
Calcium  
 Calcium is the most abundant mineral in the body and 99% of it is stored in the 
bone (Beto, 2015).  It plays a role in vascular functions, muscle contraction, hormone 
secretion, and nerve stimulation.  Dairy products like milk, yogurt, and cheese, and grains 
are major sources of dietary calcium. In the United Sates, 72% of calcium intake is 
derived from dairy products (Institute of Medicine, 2011). It is estimated that average 
intake of calcium ranges from 918 to 1,286 mg/day (Bailey et al., 2010). The 
recommended daily allowance (RDA) of calcium in adults is 1,000-1,200 mg (Ross et al., 
2011).  Because serum calcium is tightly regulated, it is not an adequate marker of dietary 
calcium. Approximately 1% of calcium is found in serum (Beto, 2015) and consists of 
free ions, protein bound complexes, and ionic complexes (Robertson et al., 1979). The
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normal range for total serum calcium is 8.5 to 10.2 mg/dL (Ross et al., 2011). Ionized 
calcium is the biologically active fraction of serum calcium (Cooper & Gittoes, 2008). 
Serum calcium homeostasis is tightly regulated for optimal cellular functions (Ladenson, 
1973) primarily by PTH and vitamin D acting on the bone, kidney, and GI tract via a 
negative feedback loop (Cooper & Gittoes, 2008). When calcium concentrations are 
lower than normal, PTH produces the active form of vitamin D (1,25(OH)2D) in the 
kidney, which stimulates osteoclasts to break down bone and enhances calcium 
absorption in the GI tract (Bushinsky & Monk, 1998). When calcium concentrations are 
elevated, PTH secretion is inhibited and production of vitamin D is reduced (Goltzman et 
al., 2018). Calcitonin, which acts as an antagonist to PTH, inhibits osteoclasts and 
decreases the reabsorption of calcium in the kidney, thus restoring serum calcium 
concentrations back into normal range (Goltzman et al., 2018). 
Phosphorus   
Phosphorus is the second most abundant mineral in the body, with most of it 
present in the bone and teeth. It plays a vital role in generation of energy, cell structure, 
and bone calcification (Takeda, 2004). Since phosphorus is naturally occurring in a 
variety of foods commonly consumed like meats, beans, nuts and seeds, dairy foods, 
grains, and food additives, phosphorus deficiencies are not very common (Vorland et al., 
2017). The RDA for phosphorus in adult men is 700 mg/day, but intake of phosphorus in 
the United States tends to exceed the recommended amount (Calvo et al, 2014). Using 
NHANES data from 2001-2014, McClure et al. (2017) found the average total dietary 
phosphorus intake for men was 1615 mg/day.  Natural sources of phosphorus absorb at a 
slower rate than phosphorus added to foods during preparation or processing (Calvo, 
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2014). Increased use of inorganic phosphate in food additives, along with increased 
consumption of processed foods in the United States, make it difficult to adequately 
capture phosphorous intake with food and nutrient databases (Calvo, 2014). Gutierrez et 
al. (2011) suggest that conventional diet assessment methods underestimate phosphorus 
intake.  
Serum phosphate levels vary based on age, but the normal range for adults is 2.5 
to 4.5 mg/dL (Penido, 2012). In comparison with calcium and PTH, the homeostatic 
mechanisms of serum phosphorus are not as controlled (Lederer, 2014). Phosphorus 
absorption primarily occurs in the intestines and is excreted via urine in the renal system 
(Chang & Anderson, 2017). Moreover, regulators of phosphate homeostasis include PTH, 
1,25(OH)2D, FGF-23, and dietary phosphate intake and absorption (Lederer, 2014; 
Penido, 2012). Although PTH increases serum calcium levels, it inhibits phosphate 
reabsorption in the kidney, thus decreasing phosphorus levels in serum (Vorland et al., 
2017). 1,25(OH)2D, on the other hand, increases phosphorus absorption in the intestine. 
FGF23, secreted though osteoclastic activity, inhibits 1,25(OH)2D production and works 
to decrease serum phosphorus (Vorland et al., 2017).   
PTH  
The parathyroid gland is comprised of four small glands that produce PTH. PTH’s 
primary function is to maintain calcium homeostasis, but it has secondary effects on 
phosphorus homeostasis. Attached to the cells of the parathyroid gland are CaSRs, which 
respond to changes in blood calcium levels and stimulate release when calcium levels are 
lower than normal or inhibit PTH when calcium levels are elevated (Goltzman et al., 
2018). PTH regulates calcium and phosphorus homeostasis in three organ systems: bone, 
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gastrointestinal tract, and kidney (Goltzman et al., 2018). When serum calcium levels are 
below normal, PTH stimulates osteoclasts to breakdown bone, which releases calcium 
and phosphorus into the bloodstream (Quarles, 2008). In the kidney, PTH activates 
1,25(OH)2D, which increases absorption of calcium and phosphorus in the intestine 
(Goltzman et al., 2018; Vorland et al., 2017). PTH increases excretion of phosphorus in 
the kidney, reducing serum phosphorus concentrations (Quarles, 2008). Under healthy 
homeostatic control, elevated calcium levels will inhibit the release of more PTH 
(Goltzman et al, 2018; Quarles et al., 2008). 
Biological Mechanisms and Implications for Prostate Cancer  
 The association between dietary calcium intake and risk of prostate cancer has 
been well-studied, and studies generally suggest high calcium intake increases prostate 
cancer risk (Aune et al., 2015; Rahmati et al., 2018; Gao et al., 2005). High calcium 
intake has been associated with lower concentrations of circulating vitamin D 
(Giovannucci et al., 2006), and vitamin D is hypothesized to decrease risk of prostate 
cancer, though not all studies are supportive (Song et al., 2018). Evidence on the 
association between phosphorus intake and prostate cancer is inconsistent and limited. 
Studies have found that high phosphorus intake is associated with increased risk of 
advanced disease (Giovannucci et al., 2006; Wilson et al., 2015), while others found a 
non-significant increase in risk of prostate cancer (Mitrou et al., 2007) or no association 
(Tseng et al., 2005). 
It is hypothesized that high phosphorus intake stimulates PTH, which is thought 
to aid in the development of prostate cancer cells (Ritchie et al., 1997). PTH related 
proteins (PTH-rp) are substantially increased in prostate cancer and expressed in over 
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90% of specimens of localized prostate cancer (Bryden et al., 2002). The preferential 
target organ for prostate cancer metastases is the bone (Davila et al., 2015). It is 
hypothesized that PTH-rp, which is involved in bone formation, promotes prostate cancer 
tumor development and may be a mediator in turning cells to bone metastases (Liao et 
al., 2008). In stratified analyses, Brandstedt et al. (2016) observed that in the presence of 
higher serum calcium concentrations, the risk for prostate cancer aggressiveness 
significantly increased among those in the highest quartile of serum PTH.  
Both normal and cancerous prostate cells have calcium receptors (Feng et al., 
2014). Several studies have reported no association between the risk of prostate cancer 
and high serum calcium concentration (Halthur et al., 2009; Skinner & Schwartz, 
2008). Though no association between high calcium concentration and prostate cancer 
risk was found, men with high levels of serum calcium were at an increased risk of fatal 
prostate cancer (Skinner & Schwartz, 2008; Schwartz & Skinner, 2012). Results from a 
study in Caribbean men of African ancestry showed a positive association between serum 
calcium and prostate cancer risk (Jackson et al., 2015). In contrast, results from studies 
conducted by Halthur et al. (2009) and Salem et al. (2013) suggest that high serum 
calcium concentrations in specific groups of men may be a protective factor in prostate 
cancer risk.  Interestingly, Bradstedt et al. (2016) observed an inverse association 
between serum calcium (in the highest quartile) and aggressive prostate cancer in the 
presence of low concentrations of PTH. On the contrary, some studies report low serum 
calcium tends to be more prevalent among patients with advanced and metastatic prostate 
cancer (Sarwar et al., 2017; Raskin et al., 1973). Potential hypothesis for this specific 
trend is excess secretion of calcium deposition into the bone during osteoblastic 
   
15 
metastases, which decreases serum calcium concentrations (Sarwar et al., 2017; Skinner 
& Schwartz, 2008). Thus, it is possible that low serum calcium is an effect of metastases 
or advanced disease rather than a cause. 
Potential Confounders  
Age  
The risk of prostate cancer increases as men age, and recent evidence suggests 
that older men have an increased risk of aggressive prostate cancer specifically (Brassell 
et al., 2011, Muralidhar et al., 2015). The average age at prostate cancer diagnosis is 66 
years (Rawla, 2019).  Using data from nationally representative cancer registries, Siegel 
et al. (2019) found the probability of being diagnosed with prostate cancer is highest 
among men 70 and older and lowest among men 49 and younger. In relation to race, AA 
men are more likely to develop prostate cancer at a younger age as compared to EA men 
(Nettey et al., 2018). The increased risk could be attributed to chronic inflammatory 
responses induced by changes in genetic and physiological features that accompany 
advancing age (Nguyen et al., 2014; Vaidyanathan et al., 2016). 
Race 
The prostate cancer incidence and mortality rates for AA men are more than twice 
that of EA men (O'Keefe et al., 2015).  Racial differences in prostate cancer incidence, 
aggressiveness, and survival are influenced by socioeconomic and environmental factors 
impacting AAs, but these factors do not completely explain the disparities observed. 
Nonetheless, research suggests that there are genetic ancestry related factors that 
influence clinicopathological features of prostate cancer (Yamoah et al., 2015). Several 
studies have found that those with increasing West African ancestry tend to have an 
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increased risk of prostate cancer and/or aggressive disease (Grizzle et al., 2019; Giri et 
al., 2009; Conti et al., 2017). 
SES  
 Socioeconomic status (SES) is a leading indicator of health status. In the United 
States, it is estimated that nearly 34% of cancer deaths between the ages of 25 to 74 
would be prevented if socioeconomic disparities did not exist (Siegel et al., 2018). 
Several studies have found that lower SES is associated with increased risk of late stage 
and advanced prostate cancer diagnosis (Byers et al., 2008; Clegg et al., 2009). Men with 
a high SES are more likely to be diagnosed with but have lower mortality rates of 
prostate cancer (Cheng et al., 2009; Singh et al., 2017). A hypothesis between these 
observed trends is that men with a higher SES tend to have more access to medical 
facilities and screening to be diagnosed, and access to treatment they can afford (Rundle 
et al., 2013). In contrast, men with lower SES are more likely to be uninsured and face 
inequities regarding access to adequate medical care, screening, and treatment (Singh et 
al., 2011).   
BMI 
 In the United States, 71% of men are overweight or obese (Odgen et al., 2014).  In 
2012, it was estimated that approximately 4% of incident cases of cancer in men in the 
United States were attributed to overweight or obesity (Arnold et al., 2015).  Results from 
a meta-analysis of prospective studies suggest a direct association between risk of 
advanced prostate cancer and BMI (Discacciati et al., 2012). Moreover, Vidal et al. 
(2014) observed that although obesity was not associated with risk of overall prostate 
cancer, it was significantly associated with an increased risk of aggressive disease.  
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Excess body fat in men tends to be accompanied by higher insulin levels, leptin 
concentrations and insulin-like-growth-factor-1, which have all been associated with 
progression of prostate cancer (Mistry et al., 2007). Additionally, obesity promotes 
systemic inflammation, which is hypothesized to play a role in prostate cancer 
aggressiveness (Gurel et al., 2014; Stark et al., 2015). 
Family history  
Family history is another well-established risk factor for prostate cancer. Men 
with a first degree relative with prostate cancer have double the risk of developing 
prostate cancer, and this trend is consistent across racial and ethnic groups (Whittemore 
et al., 1995; Barber et al., 2018). Furthermore, the risk of prostate cancer increases with 
the number of relatives affected (Chen et al., 2008). Family history of prostate cancer 
also contributes to risk of aggressive and non-aggressive prostate cancer by nearly two-
fold (Chen et al., 2008) and lethal prostate cancer by 72% (Barber et al., 2018). Family 
history encompasses both genetic predispositions to prostate cancer and shared lifestyle 
factors. Results from a twin study suggest that the heritability of prostate cancer is 
approximately 58% (Hjelmborg et al., 2014).   
Screening History   
 There are two commonly used screening tools for prostate cancer - digital rectal 
exam (DRE) and prostate specific antigen (PSA). The DRE allows a physician to 
examine the prostate for abnormalities and is often used in combination with the PSA. 
The DRE has been reported to have low sensitivity in primary care settings (Naji et al., 
2018) and only fair reproducibility among urologists, (Smith & Catalona, 1995). 
Furthermore, results from a study conducted by Okotie et al. (2017) found that prostate 
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cancers detected by abnormal DRE and PSA tests were more likely to be clinically 
aggressive as compared to prostate cancers detected by either test alone (Okotie et al., 
2007).   
 High PSA levels are associated with prostate cancer risk, but could be caused by 
other benign diseases of the prostate (Eastham, 2017). When the PSA screening test was 
approved for prostate cancer detection in the 1990’s, the incidence rate of prostate cancer 
surged (Potasky, 1995). Consequently, in 2012, the USPSTF recommended against 
routine PSA screenings for diagnosis due to a substantial increase in diagnosis of prostate 
cancer cases that would either not progress or remain asymptomatic, (Moyer, 2012).  
Following these recommendations, a dramatic decrease in PSA testing was observed, 
raising concerns that this trend could be accompanied by an increase in late stage 
diagnosis and poorer survival (Patel, 2018; Ahlering, 2019). As an update to the 2012 
recommendations, in 2018 the USPSTF suggested that the decision to get PSA screening 
among men 55 to 69 years old should be influenced by factors like race/ethnicity, family 
history, and individualized values (Grossman et al., 2018). However, it remained a 
recommendation that men older than 70 not be screened.   
Vitamin D  
 Vitamin D has been found to mediate biological responses that aid in cancer 
prevention, cell death, and inhibit the growth of tumors (Chakraborti, 2011). Though 
vitamin D has been studied for its potential beneficial effects for various cancers 
(McCullough et al., 2019; Guo et al., 2018), evidence on the influence of vitamin D on 
prostate cancer is inconsistent.  In a study conducted by Albanes et a (2011), men with 
higher serum concentrations of vitamin D were at an elevated risk of prostate cancer. In 
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the North Carolina-Louisiana Prostate Cancer Project (PCaP), higher serum 25 hydroxy-
vitamin D [25(OH)D] concentrations were associated with increased odds of aggressive 
prostate cancer in AA men, but had no association in EA men (Steck et al., 2015). In a 
different study, however, Ahn et al. (2008) reported no association between prostate 
cancer risk and vitamin D concentration. In contrast, several studies report that vitamin D 
deficiency increases risk of aggressive prostate cancer (Gilbert et al., 2012; Shui et al., 
2012; Nelson et al., 2017). After observing a strong inverse association between tumor 
vitamin D receptors (VDR) expression and risk of lethal prostate cancer, Hendrickson et 
al. (2011) suggest that expression of VDR is a predictive marker of prostate cancer 
development via a biological pathway. 
NSAIDs  
Chronic inflammation is thought to play a role in prostate cancer development 
(De Marzo, 2007) and has been associated with high grade, aggressive disease (Gurel et 
al., 2014; Klink et al., 2013). Nonsteroidal anti-inflammatory drugs (NSAIDs) like 
aspirin inhibit cyclooxygenase-2, which are enzymes that promote inflammation and 
are independently associated with prostate cancer (Partin, 2001; Cheng, 2007). The lines 
of evidence on NSAID use and prostate cancer are inconsistent. While some studies 
suggest an inverse association between NSAID use and prostate cancer incidence and 
aggressiveness (Vidal et al., 2015; Doat et al., 2017), evidence from other studies suggest 
no association (Brasky et al., 2010). 
Charlson Comorbidity Index  
 The Charlson Comorbidity Index (CCI) (Charlson et al., 1987) was developed as 
a weighted index that measures an individual’s burden of morbidities and uses this 
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information to predict mortality. Comorbidities are common among people diagnosed 
with cancer, with approximately 31% of prostate cancer cases reporting comorbidity 
(Edwards et al., 2014). Moreover, the CCI is commonly used among clinicians and 
patients to help guide prostate cancer prognosis and treatment decisions (Berglund et al., 
2011; Albertsen et al., 2011). Higher comorbidity scores tend to be associated with 
poorer disease prognosis and survival, with some suggesting this is due to prostate cancer 
(Edwards et al., 2014) and others competing risks (Rajan et al., 2017).  
 Alcohol Intake  
 The association between alcohol consumption and risk of prostate cancer is 
inconclusive.  A meta-analysis reports increased risk of prostate cancer among all levels 
of alcohol consumption with a dose-response relationship (Zhao et al., 2016). However, 
results from a Mendelian randomization study suggest that alcohol consumption does not 
influence prostate cancer risk, but it may influence disease progression (Brunner et al., 
2017). Comparably, Michael et al. (2018) found that although current alcohol use was not 
associated with prostate cancer risk, high lifetime intake of alcohol was associated with 
increased risk of aggressive disease at diagnosis. Inconsistencies in associations could be 
explained by issues with recall bias in case-control studies, measurement error due to 
self-report of alcohol intake, and overlapping categories of current drinkers versus former 
drinkers and lifetime intake versus current intake (Michael et al., 2018, Zhao et al., 2016). 
Smoking Status  
 Smoking is a source of established carcinogens (Hecht, 2006) and has been 
associated with an increased risk of various types of cancer (Bosetti et al., 2012; 
Freedman et al., 2011; Okeeffe et al., 2018). However, the association between prostate 
   
21 
cancer and smoking is inconclusive. Results from a pooled analysis of 24 cohort studies 
found that when stratified by amount smoked, current smokers had an increased risk of 
incident prostate cancer (Huncharek, 2010). In contrast, a prospective cohort study 
reported that current smokers were less likely to be diagnosed with prostate cancer 
(Watters et al., 2009). Ho et al (2014) found that although current smokers had an 
increased risk of aggressive prostate cancer (OR:1.44, 95% CI:1.04, 2.00), current 
smoking was not associated with risk of low-grade or total prostate cancer. Regarding 
race, Murphy et al. (2014) found an association between heavy smoking in AA men and 
odds of aggressive prostate cancer and prostate cancer risk, but no association was 
observed among EA men. 
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Table 2.1: Summary table of studies that examined the associations between calcium, phosphorus, PTH, 
and prostate cancer outcomes 
Lead 
Author
, Yr 
Study 
Design, 
Number 
of 
Subjects, 
Location 
Outcome(s) Exposures  Confounders Effect 
Modifiers 
Results 
   Ca P PTH  
Jackson 
et al., 
2015 
Case 
control, 
224 
cases, 
248 
controls, 
Jamaica 
Prostate 
cancer 
Yes 
(dietary 
and 
serum) 
No No BMI, 
education, 
family 
history, 
physical 
activity, 
smoking, 
supplement 
use; 
25(OH)D, 
phosphorus, 
and serum 
calcium as 
appropriate 
Age, BMI, 
family 
history 
[OR, (95% 
CI)] 
T3 vs T1 
Dietary 
calcium: 
0.74 (0.36-
1.53) 
 
Serum 
calcium: 
1.35 (0.80-
2.29) 
Schwar
tz et al., 
2012 
Cohort, 
6707, 
USA 
Fatal 
prostate 
cancer 
Yes 
(serum 
ionized 
and 
total) 
No No Age, BMI, 
serum 
albumin, 
serum 
25(OH)D 
None [RH, (95% 
CI)] 
Ionized 
calcium: 
Deaths 0-8 
years 
T3 vs T1 
 
 
2
3
 
4.46 (0.89-
22.36) 
Continuous 
1.73 (1.13-
2.63) 
Deaths 8+ 
years 
T3 vs T1  
1.01 (0.23-
4.43) 
Continuous 
0.82 (0.35-
1.95) 
 
Total 
calcium: 
Deaths 0-8 
years 
T3 vs T1 
1.76 (0.46-
6.78) 
Continuous 
1.49 (1.04-
2.14) 
Deaths 8+ 
years 
T3 vs T1  
1.08 (0.26-
4.41) 
Continuous 
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0.75 (0.57-
0.99) 
 
Skinner 
et al., 
2008 
Cohort 
2814, 
USA 
Incident and 
fatal 
prostate 
cancer 
Yes 
(serum) 
No No Age, BMI, 
race, family 
history 
None [RH, (95% 
CI)] 
T3 vs T1 
Incidence: 
1.31 (0.77-
2.20) 
 
Mortality: 
2.68 (0.94-
7.64) 
 
Salem 
et al., 
2013 
Case 
control, 
194 
cases, 
317 
controls, 
Iran, 
 
Risk of 
prostate 
cancer 
Yes 
(serum) 
No No Age, BMI, 
occupation, 
education 
level, 
smoking 
alcohol, 
marital status, 
family 
history, sex 
hormones 
None [OR, (95% 
CI)] 
T3 vs T1 
Total 
calcium: 
0.27 (0.12-
0.59) 
 
Corrected 
calcium: 
0.25 (0.10-
0.58) 
Halthur 
et al., 
2009 
Cohort, 
22391, 
Sweden 
Risk of 
prostate 
cancer 
Yes 
(serum) 
No No Age, smoking 
status, BMI, 
marital status, 
socioeconomi
c index, 
BMI and 
age 
[HR, (95% 
CI)] 
Q4 vs Q1 
0.94 (0.81-
1.08) 
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alcohol 
consumption 
Van 
Hemelr
ijck et 
al., 
2012 
Cohort, 
196022, 
Sweden 
Incident and 
fatal 
prostate 
cancer 
Yes 
(serum) 
No No SES, albumin, 
Charlson 
comorbidity 
index 
Age and 
overweight 
[HR, (95% 
CI)] 
Incident: 
Q4 vs Q1 
Total: 
0.92 (0.85-
0.99) 
Albumin 
corrected: 
0.91 (0.85-
0.98) 
 
Aggressive: 
Q4 vs Q1 
Total: 
1.10 (0.85-
1.41) 
Albumin 
corrected: 
1.14 (0.89-
1.45) 
 
Mortality 
Q4 vs Q1 
Total: 
0.95 (0.82-
1.28) 
Albumin 
corrected: 
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1.02 (0.82-
1.26) 
 
Brandst
edt et 
al., 
2016 
Nested 
case 
control, 
943, 
Sweden 
Tumor 
aggressiven
ess 
Yes 
(serum) 
No Yes  Age, 
screening 
month and 
year, BMI, 
education 
level, alcohol 
consumption, 
smoking 
status 
Vitamin D, 
PTH, 
calcium 
[OR, (95% 
CI)] 
Q4 vs Q1 
Non-
Aggressive  
PTH: 
0.75 (0.56-
1.01) 
Calcium: 
1.11 (0.82-
1.50) 
 
Aggressive 
PTH: 
0.87 (0.59-
1.30) 
Calcium: 
1.00 (0.68-
1.47) 
Wilson 
et al., 
2015 
Cohort, 
47885, 
USA 
Prostate 
cancer risk 
and 
aggressiven
ess 
Yes 
(dietary) 
Yes 
(dietary) 
No Age, calendar 
time, race, 
height, BMI, 
at age 21, 
current BMI, 
vigorous 
physical 
activity, 
smoking, 
None [RR, (95% 
CI)] 
Calcium: 
High vs ref 
All cancer  
1.16 (0.95-
1.43) 
High grade 
cancer:  
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diabetes, 
family 
history, 
intakes of 
tomato 
sauce, α-
linolenic acid, 
supplemental 
vitamin E, 
alcohol, 
energy intake, 
multivitamin 
use, history of 
PSA, dairy, 
animal 
protein, 
phosphorus, 
calcium 
1.51 (.088-
2.59) 
Low grade 
cancer: 
0.76 (0.52-
1.11) 
 
Phosphorus: 
Q5 vs Q1 
All cancer:   
1.13 (1.00-
1.27) 
High grade 
cancer:  
1.51 (1.06-
2.17) 
Low grade 
cancer: 
1.03 (0.85-
1.24) 
Chan et 
al., 
2000 
RCT, 
27111, 
Finland 
Prostate 
cancer risk 
Yes 
(dietary) 
Yes 
(dietary) 
No Intervention 
group, 
education, 
age, BMI, 
energy, 
number of 
years as a 
smoker 
Calcium 
and 
phosphorus 
[RR, (95% 
CI)] 
Q5 vs Q1 
Calcium 
1.6 (0.8-3.0) 
 
Phosphorus 
0.8 (0.4-1.5) 
Tavani 
et al., 
2005 
Case 
control,  
Prostate 
cancer risk 
Yes 
(dietary) 
Yes 
(dietary) 
No Age, center, 
education 
BMI, tobacco 
Age, 
education, 
BMI, total 
[OR, (95% 
CI)] 
Q5 vs Q1 
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1294 
cases, 
1451 
controls, 
Italy 
smoking, 
physical 
activity, total 
energy, family 
history 
energy 
intake, 
family 
history 
Calcium: 
1.18 (0.88-
1.59) 
 
Phosphorus: 
1.20 (0.79-
1.84) 
Kesse 
et al., 
2005 
RCT,  
2805, 
France 
Prostate 
cancer risk 
Yes 
(dietary) 
Yes 
(dietary) 
No Occupation, 
treatment 
group, 
smoking 
status, overall 
physical 
activity, 
energy from 
fat, energy 
from other 
sources, 
ethanol 
intake, BMI, 
family history 
Calcium 
and 
Phosphorus 
[RR, (95% 
CI)] 
Total 
calcium: 
2.43 (1.05-
5.62) 
 
Phosphorus: 
1.83 (0.89-
3.73) 
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CHAPTER 3 
RESEARCH METHODS 
 
1. Background  
The data from this study are derived from the North Carolina-Louisiana Prostate 
Cancer Project (PCaP), a population-based study consisting only of prostate cancer 
cases, designed to examine racial differences in prostate cancer aggressiveness. PCaP 
consists of 1,130 AA cases and 1,128 EA cases from North Carolina and Louisiana. This 
research is a component of an ancillary PCaP study titled “Vitamin D and Related Genes, 
Race and Prostate Cancer Aggressiveness” funded by the Department of Defense (Grant 
# DAMD-11-1-0568; PI: S. Steck).   
2. PCaP Methods  
Study Population  
 In the paper, “The North Carolina-Louisiana Prostate Cancer Project (PCaP): 
Methods and Design of a Multidisciplinary Population-Based Cohort Study of Racial 
Differences in Prostate Cancer Outcomes”, Schroeder et al. (2006) stated: “residents of 
the North Carolina and Louisiana study areas with a first diagnosis of histologically 
confirmed adenocarcinoma of the prostate [were] eligible to participate if they [were] 40-
79 years old at diagnosis, [could] complete the study interview in English, [did] not live 
in an institution (nursing home), [were] not cognitively impaired or in a severe debilitated   
physical state, and [were] not under the influence of alcohol, severely medicated, or 
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apparently psychotic at the time of interview. Eligible men also must self-identify as at 
least part African American/Black or Caucasian American/White in response to the open-
ended interview question, ‘what is your race?’ Participants who indicated more than one 
group [were] asked if one best described them; if not, multiple groups [were] recorded. 
This classification may be used as a proxy measure of race as a biologic construct, as 
deemed appropriate for the individual PCaP Consortium projects. Participants [were] 
asked if they consider themselves to be Cajun, Creole, or Hispanic/Latino prior to the 
question about race, so that these ethnic groups [were] defined independent of African 
American or Caucasian American race/ethnicity.   
North Carolina enrollment of patients from 42 counties diagnosed on or after July 
1, 2004, began in September 2004. The North Carolina study area consists of 42 counties. 
Louisiana enrollment began in 13 parishes surrounding New Orleans in September 2004, 
but was discontinued because of Hurricane Katrina (August 29, 2005). This period of 
data collection (referred to as Louisiana Phase I) included study visits with 122 African 
American and 95 Caucasian American participants”. A second phase of Louisiana 
enrollment was attained in an expanded study area (including at least eight additional 
parishes in southern Louisiana).” 
Rapid Case Ascertainment  
“Eligible North Carolina patients [were] identified by the Rapid Case 
Ascertainment Core Facility, a collaborative effort of the UNC-Lineberger 
Comprehensive Cancer Center and the North Carolina Central Cancer Registry 
(NCCCR). North Carolina state law mandates regular reporting of all newly diagnosed 
cancers (excluding non-melanoma skin cancers), and the NCCCR is authorized to release 
 
 31 
contact and eligibility information to PCaP by the North Carolina Advisory Committee 
on Cancer Coordination and Control. In Louisiana, eligible patients [were] identified by 
the Louisiana Tumor Registry (LTR) in the School of Public Health at LSUHSC. LTR 
operations are mandated by Louisiana law, which directs all hospitals, pathology 
laboratories, health care facilities, and medical care providers to report cancer cases or 
provide LTR staff with access to this information. Case ascertainment field 
representatives abstract[ed] pathology reports, review[ed] information used to screen 
eligibility and ensure[d] that ascertainment in hospitals and local urology clinics [was] as 
complete and rapid as possible. These data [were] entered into a relational database that 
[was] regularly downloaded into the PCaP Subject Tracking Database” (Schroeder et al., 
2006).  
Randomized Recruitment  
“Caucasian Americans account[ed] for a greater proportion of North Carolina 
patients than African Americans; therefore, a randomized recruitment procedure [was] 
used to generate comparable ascertainment and enrollment rates by race and state over 
the entire enrollment period. This sampling method improve[d] efficiency without 
compromising estimation of main effects and risk difference modification (additive scale 
37 interactions) by race, and appropriate analysis requires only that the sampling 
probabilities are included as stratum-specific offset terms in some analytic models. To 
apply randomized recruitment, each ascertained case [was] assigned a random number 
and recruited only if that number [was] less than or equal to its race specific sampling 
probability, which is 100% for African Americans and 44% for Caucasian Americans” 
(Schroeder et al., 2006).  
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Physician Notification  
 “Recruitment [began] with a mailed request to the diagnosing physician for 
permission to contact their patient, as mandated by the North Carolina and Louisiana 
cancer registries. Written physician permission [was] not required; instead, physicians 
[were] given 3 weeks to notify PCaP if a patient should not be contacted for any reason, 
including ineligibility due to mental illness or impairment, nursing home residence, or 
severe physical debilitation. Passive physician permission, and access to patient 
information under a limited waiver of consent to identify and contact potential PCaP 
participants, was approved by the UNC and LSUHSC IRBs and DoD HSRRB” 
(Schroeder et al., 2006).  
Enrollment  
“Patients with active or passive physician consent [were] sent an introductory 
letter and brochure describing PCaP. One week later an experienced enrollment specialist 
[called] to confirm eligibility, explain the study, answer questions, solicit participation, 
and schedule an in home visit. Demographic and pathology report data (without 
personally identifiable information) [were] retained for cases who could not be contacted 
or who decline[d] participation, so that characteristics of non-participants could be 38 
compared with those of participants to assess potential selection bias. Reasons for 
declining participation [were] recorded when known. Enrollment specialists [were] 
required to make multiple attempts to contact each potential participant. If a valid phone 
number could not be identified, the patient’s urologist [was] asked to provide the patient 
with the PCaP introductory letter at his next appointment. Patients who could not be 
contacted within 90 days [were] sent a letter asking them to contact the study directly. If 
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no contact [was] made within the next 30 days, the patient [was] classified as ‘unable to 
contact’.” (Schroeder et al., 2006).  
Study Visit  
 “Participants [were] visited in their home (or other location of their choosing) by 
a trained Registered Nurse. Participants [were] asked to fast for 6 hr prior to the study 
visit, which [was] scheduled in the morning whenever possible, and to gather all 
medications and supplements used in the 2 weeks prior to the visit. Study nurses [began] 
each visit by explaining the study and obtaining HIPAA authorization and formal written 
informed consent to: (1) conduct the questionnaire interview, (2) make anthropometric 
measurements, (3) obtain samples of adipose tissue, blood, urine, and toenails, (4) allow 
temporary release of paraffin embedded prostate tissue blocks, and (5) allow retrieval and 
abstraction of medical records. Study consent forms [were] read aloud to illiterate 
participants in the presence of a witness not associated with PCaP. After consent forms 
[were] signed, the study nurse collect[ed] biologic samples, [made] anthropometric 
measurements and administer[ed] the questionnaire. Study visits [took] approximately 4 
hr to complete, including two 15-min breaks. Participants [were] partially compensated 
for their time with a payment of up to $75 for completing the entire PCaP study visit. All 
study visit protocols [were] documented in a manual of procedures. To ensure 
consistency, patient safety, and confidentiality, study nurses must be certified and 
periodically re-certified to conduct all aspects of the visit. Interview and biologic sample 
collection data [were] reviewed on an ongoing basis to identify variation among study 
nurses or between study sites that cannot be explained by acceptable or expected trends. 
In addition, project managers at each site call randomly selected study participants after 
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study visits [were] completed to assess nurse performance and solicit feedback” 
(Schroeder et al., 2006).  
Anthropometric Measures  
“Weight (to the nearest 0.1 kg), height, and waist and hip circumferences (in cm) 
[were] measured after biologic sample collection using standardized instruments. 
Participants [were] asked their usual weight and height at age 25 and their weight 1 year 
prior to the visit” (Schroeder et al., 2006).  
Study Questionnaires  
“Study nurses administer[ed] a series of structured questionnaires that solicit[ed] 
information regarding: Background characteristics: self-described race and ethnicity, 
marital status, religion, education, income, tobacco use, physical activity.   
Occupation: current employment, occupation and industry, longest and second 
occupation and industry, military service, occupations associated with pesticide use.   
Family history: prostate cancer in first- and second-degree relatives.   
Health status: general health and comorbid conditions.   
Health care: usual sources of care, health insurance, traditional health beliefs, perceived 
access, and quality of care.   
Prostate cancer diagnosis and screening history: PSA tests, digital rectal exams, urinary 
and sexual symptoms, previous prostate biopsies.  
Medication survey: all prescription and over-the-counter medications and supplements 
used in the prior 2 weeks (transcribed by study nurses).   
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Non-steroidal anti-inflammatory drugs (NSAIDs): frequency and duration of use for 
prescription and over-the-counter NSAIDs taken during the past 5 years at least once a 
month for 1 week or longer, with product name show cards to aid recall.   
Vitamins and supplements (including herbal products).  
Diet History Questionnaire (DHQ): The DHQ was developed by the National Cancer 
Institute and modified by PCaP Project 3 investigators to include Southern foods. The 
DHQ asks about intake frequency and usual portion size for 124 food items, as well as 
food preparation methods. Participants are asked to recall their usual diet for the year 
prior to diagnosis. Questionnaire responses are linked to the updated DHQ Nutrient 
Database through the NCI-developed Diet*Calc software to estimate intake of macro- 
and micronutrients” (Schroeder et al., 2006).  
Medical Record Retrieval and Abstraction  
“Medical records [were] requested from the diagnosing physician of consenting 
participants. Trained staff use[d] a relational database designed specifically for PCaP to 
abstract information concerning comorbid conditions, family history of prostate cancer, 
urologic symptoms, indications for diagnostic examinations and biopsies, prostate cancer 
41 screening examinations, and laboratory assays at or near diagnosis, imaging 
examinations used in staging, clinical stage and grade (as recorded), and initial treatment 
information. In addition, abstractors independently derive[d] clinical stage according to a 
standardized protocol. Pathologic stage, grade, and other prostatectomy data [were] 
recorded separately, when available” (Schroeder et al., 2006). To ensure consistency 
between abstractors, approximately 10% of medical records were abstracted by a second 
abstractor and concordance was ascertained. 
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Blood Samples and Laboratory Assays  
During the study visit, nurses collected approximately 42 ml of blood from 
consenting participants: serum was removed from red top tubes and aliquoted into 10 
cryovials. Plasma was removed from yellow-top tubes and lavender top (EDTA) tubes, 
and DNA was purified from white blood cells. Louisiana samples were shipped overnight 
to the Tissue Procurement Facility at UNC-CH for processing. DNA, plasma and serum 
are stored at -80°C at UNC-CH. Appropriate volumes of biologic samples were aliquoted 
and shipped overnight on dry ice to the labs at UCLA and University of South Carolina 
for assays.  
Serum calcium and phosphorous were measured at the Clinical Laboratories of 
Pathology and Laboratory Medicine, UCLA Medical Center using standard colorimetric 
methods. Intact PTH (84 amino acid chain) was measured in plasma samples using an 
Enzyme-Linked ImmunoSorbent Assay (ELISA) from ALPCO (Salem, NH) at the 
University of South Carolina.  Briefly, calibrators, controls and patient samples were 
simultaneously incubated with an enzyme labeled antibody and a biotin coupled antibody 
in a streptavidin-coated microplate well.  Following the incubation period the wells were 
washed to remove unbound components and the enzyme bound to the solid phase was 
incubated with a substrate, tetramethylbenzidine (TMB).  An acidic stopping solution 
was added to stop the reaction. The intensity of color measured on a microplate reader at 
450nm was directly proportional to the concentration of intact PTH in the sample. 
Sensitivity of this kit is calculated at 1.72pg/mL. Plasma concentrations of 25(OH)D3 
were determined using LC-MS/MS at Heartland Assays, Inc.  
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3. Variables  
Primary Outcome  
Prostate cancer aggressiveness was classified based on clinical grade (Gleason 
grade), clinical stage, and PSA at diagnosis. “PCaP participants were categorized into 
three categories of aggressiveness: High aggressive cases: Gleason sum ≥ 8, or PSA >20 
ng/ml at diagnosis, or Gleason sum = 7 AND stage T3-T4; low aggressive cases: Gleason 
sum <7 AND diagnosed at stage T1-T2 AND PSA <10 ng/ml at diagnosis; intermediate 
aggressive cases: all other cases. For the present study, all PCaP research subjects 
diagnosed with high aggressive cancer and intermediate aggressive cancer subjects who 
had Gleason sum = 7 with primary Gleason pattern 4 were combined into the high 
aggressive group. The high aggressive group was compared to a “control” group, which 
consisted of a random sample of low aggressive cases with Gleason sum <7, stage T1-T2, 
and PSA<9 ng/ml” (Steck et al., 2015). 
Main Exposures: Calcium, Phosphorus, and PTH  
Serum Calcium: Expressed in quartiles based on the distribution among low aggressive 
cases  
Serum Phosphorus: Expressed in quartiles based on the distribution among low 
aggressive cases  
Plasma Parathyroid Hormone (PTH): Expressed in quartiles based on 
the distribution among low aggressive cases  
Based on sample size, we categorized the exposure variables into quartiles. However, we 
added a fifth category to determine if increased risk is apparent in higher categories of the 
exposure variables. In addition, there are clinical guidelines about normal ranges for each 
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of circulating calcium, phosphorus, and PTH which we explored using as cutpoints when 
categorizing these variables. Finally, we examined distributions of the three variables by 
race to determine if race-specific cutpoints were necessary (as was done in the PCaP 
vitamin D metabolites papers previously) (Steck et al., 2015; Ramakrishnan et al., 2019).  
Potential Confounders and/or Effect Modifiers  
Age: Included as a continuous covariate (reported in years)  
Alcohol Intake: Included as a continuous variable (reported in servings per day)  
BMI: Included as a continuous variable in main effects analysis and categorical variable 
in stratified analysis (normal [18.5–24.9 kg/m2], overweight/obese [≥ 25.0 kg/m2]) 
Comorbidity: Using the Charlson Comorbidity Index, scores were categorized as 0, 1-2, 
and ≥ 3 in main effects analysis and dichotomized as 0 comorbidities and ≥ 1 
comorbidities in stratified analysis. 
Education: Categorized into four levels: less than high school, high school graduate or 
vocational/technical school; some college or college graduate; some graduate training or 
graduate/professional degree  
Family History: Dichotomized as “yes” if men reported a first degree relative with 
a history of prostate cancer and “no” for all others  
NSAIDs use: Dichotomized into “yes” for those taking NSAIDs regularly and “no” for 
all others  
Race: Classified as European American or African American  
Screening History: Defined on four levels: no previous screening history, digital rectal 
exam only, PSA only, or PSA and digital rectal exam  
Smoking Status: Divided into non-smoker, former smoker, current smoker  
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25-hydroxyvitamin D: Included as a continuous variable in main effects analysis and 
divided into quartiles based on low aggressive case distribution in joint effects analysis  
Missing Data   
Any participants missing outcome, covariate, or exposure data were not included in the 
final analyses.  
Statistical Analyses  
All procedures were performed using SAS, version 9.4 statistical software to assess:  
1. Univariate distributions of exposures, outcomes, and potential covariates. Means and 
standard deviations for continuous variables and frequencies and proportions for 
categorical variables were reported by high/low aggressive prostate cancer status and by 
race.  
2. Odds ratios and 95% CIs for high aggressive prostate cancer were calculated using 
logistic regression for each exposure variable (circulating calcium, phosphorus, and 
PTH). A simple model included adjustment for age and race, and separately stratified by 
race (Specific Aim 1).   
3. Odds ratios and 95%CIs for high aggressive prostate cancer were calculated using 
multivariable logistic regression models adjusted for age, race, plasma 25(OH)D, alcohol 
intake, family history, smoking status, NSAIDs use, education, screening history, BMI, 
and CCI. The decision to include these covariates in the model was based on previous 
relevant literature. Models for circulating calcium, phosphorus, and PTH were mutually 
adjusted for each other (Specific Aim 1). 
4. P-values for trend test of quartile categories of calcium, phosphorus, and PTH were 
calculated by using the continuous variable in the logistic regression model.  
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 5. Joint associations of circulating calcium, phosphorus, PTH, and 25(OH)D were 
examined using a common referent group and comparing all other combinations to the 
common referent group. Interaction p-values were determined by including an interaction 
term in the adjusted models (Specific Aim 2).  
6. Effect modification by smoking, comorbidity, and BMI were examined for each 
exposure variable (circulating calcium, phosphorus, and PTH) using stratified analyses. 
Interaction p-values were determined by including an interaction term in the adjusted 
models (Specific Aim 3).  
7.  Pearson correlations for circulating calcium, phosphorus, and PTH were calculated for 
all men.
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CHAPTER 4 
RESULTS 
Tables 4.1-4.2: Descriptive Statistics 
 Subjects missing data on prostate cancer aggressiveness, serum calcium, serum 
phosphorus, plasma PTH, and/or any of the covariates were excluded. The final sample 
size consisted of 783 low aggressive prostate cancer cases and 405 high aggressive 
prostate cancer cases, of which 529 were AA (41.4% high aggressive) and 659 were EA 
(28.2% high aggressive). High aggressive cases were slightly older at time of diagnosis 
compared to low aggressive cases (Table 4.1). Most high aggressive and low aggressive 
cases reported no family history of prostate cancer (71.1% high aggressive vs 66.4% low 
aggressive). The mean (±SD) serum calcium level did not substantially differ by race (9.3 
± 0.5 mg/dL in AAs vs 9.2 ± 0.4 mg/dL in EAs) (Table 4.2). The mean serum phosphorus 
level (±SD) in AA and EA men was similar at 4.3 ± 2.4 mg/dl and 4.3 ± 2.3 mg/dl, 
respectively. The mean (±SD) concentration of plasma PTH was higher among AA men 
(49.2 ± 35.7 pg/mL) than EA men (43.3 ± 23.9 pg/mL).  
Tables 4.3-4.4: Main Effects in the Total Population 
 As shown in Table 4.3, circulating calcium, phosphorus, and PTH were first 
categorized into quartiles based on the distribution among low aggressive cases. Though 
not statistically significant, an inverse association was observed between serum calcium 
and aggressive prostate cancer (ORQ4vsQ1: 0.75, 95% CI: 0.51-1.09). For serum 
phosphorus, a higher odds of aggressive prostate cancer was observed in the simple 
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model which strengthened and remained statistically significant in the adjusted model 
(OR: Q3vsQ1: 2.36, 95% CI:1.60-3.48; OR: Q4vsQ1: 2.17, 95% CI:1.43-3.29). In Table 
4.4, clinically high 5th categories of serum calcium and phosphorus were added. For  
calcium, the odds of aggressive prostate cancer reversed in the upper 5th level indicating 
higher odds of aggressive prostate cancer, though the confidence interval included the 
null value (OR: 1.44, 95% CI: 0.58-3.53). After adding the 5th category for serum 
phosphorus, the increased odds of aggressive prostate cancer remained, and the 
association maintained statistical significance (OR: 2.20, 95% CI: 1.43-3.39). An inverse 
association between the odds of aggressive prostate cancer and PTH was observed, 
though this was not statistically significant (OR:Q4vsQ1: 0.79, 95% CI:0.55-1.14) (Table 
4.3). 
Tables 4.5-4.8: Main Effects by Race 
        The observed inverse association between serum calcium and aggressive prostate 
cancer persisted in strata of EA and AA men (Table 4.5). Among EA men in the highest 
quartile of serum calcium, the odds of aggressive prostate cancer decreased by 45% 
(OR:Q4vsQ1: 0.55, 95% CI: 0.31-0.96). The association was not as strong among AA 
men (ORQ4vsQ1: 0.82, 95% CI: 0.47-1.45). For both AA and EA men, the odds of 
aggressive prostate cancer were significantly increased in the highest two quartiles of 
serum phosphorus (Table 4.6), with more pronounced results observed among EA men 
(ORQ3vsQ1:3.07, 95% CI: 1.76-5.35; OR:Q4vsQ1: 2.63, 95% CI:1.44-4.82) than AA men 
(OR: Q3vsQ1:1.82, 95% CI: 1.02-3.26; OR: Q4vsQ1: 1.88, 95% CI:1.02-3.46). There was 
no consistent association between plasma PTH and prostate cancer aggressiveness for 
either EA or AA men (Table 4.7). Among AA men in the 3rd PTH quartile, the odds  
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of aggressive prostate cancer decreased by 44% (OR: 0.56, 95% CI: 0.32-0.97). The 
mean PTH concentrations of AA men were noticeably higher than that of EA men, so 
race-specific PTH quartiles were created (Table 4.8). In the simple model, among AA  
men there was an inverse association between aggressive prostate cancer and plasma 
PTH for all three upper quartiles. Adjustment for confounders attenuated the associations 
and the results were no longer statistically significant. There was no clear association 
between aggressive prostate cancer and plasma PTH among EA within race specific 
quartiles. 
Table 4.9-4.10: Reference Ranges and Median Cutpoints 
 Clinical cutpoints for circulating calcium, phosphorus, and PTH were created 
based on reference ranges established by the NIH U.S. National Library of Medicine 
(Table 4.9). Clinically low and high serum calcium levels were associated with increased 
odds of aggressive prostate cancer, though the results were not statistically significant 
(low calcium: OR: 1.35, 95% CI: 0.58-3.18; high calcium: OR: 1.84, 95% CI:0.77-4.38 
compared to normal calcium). Among those with serum phosphorus levels below the 
normal range, the odds of aggressive prostate cancer decreased by 56% in the adjusted 
model (OR: 0.44, 95% CI: 0.27-0.71). There was indication of a moderate, non-
statistically significant increased odds of aggressive prostate cancer among men with 
serum phosphorus above the normal range (OR: 1.24, 95% CI: 0.90-1.72). The clinically 
low PTH category consisted of only 2 cases (1 low aggressive case and 1 high aggressive 
case). Due to insufficient sample size, these participants were excluded from the PTH 
analysis. There was a slight, non-statistically significant decreased odds of aggressive 
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prostate cancer among men in the clinically high PTH category (OR: 0.83, 95% CI: 0.61-
1.13). 
 Median cutpoints were established based on the 50th percentile of the low 
aggressive case distribution for circulating calcium, phosphorus, and PTH (Table 4.10). 
Among men with serum calcium levels above the median cutpoint 9.2 mg/dL, there no 
association with aggressive prostate cancer (OR: 0.90, 95% CI: 0.70-1.18). Serum 
phosphorus levels above the median cutpoint 3.3 mg/dL were associated with increased 
odds of aggressive prostate cancer (OR: 2.00, 95% CI: 1.53-2.63). The odds of aggressive 
prostate cancer among those with plasma PTH levels above the median cutpoint of 
40.63pg/ml were not significantly different than those with a plasma PTH level at or 
below the median (OR: 0.85, 95% CI: 0.65-1.10). 
Table 4.11: Joint Associations  
 The joint associations of circulating calcium, phosphorus, PTH, and 25(OH)D 
were examined using the quartile and median cutpoint variables for each analyte with the 
low-low joint category as the referent group (Table 4.11). Among those with low serum 
phosphorus (at or below 3.3. mg/dL) who were in the 2nd quartile of serum calcium the 
odds of aggressive prostate cancer decreased by 42% (OR: 0.58, 95% CI: 0.34-0.97).  
Among those with high serum phosphorus (above the median 3.3. mg/dL) and in the 
lowest quartile of serum calcium, the odds of aggressive prostate cancer increased by 
nearly two-fold (OR: 1.99, 95% CI: 1.18-3.34). As serum calcium increased, the 
increased odds of aggressive prostate cancer was attenuated among men with high serum 
phosphorus; however, the test for interaction between serum calcium and serum 
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phosphorus was not statistically significant (P=0.49). No joint effects were observed for 
serum calcium and either high or low PTH or 25(OH)D.   
 Among those in the 2nd quartile of serum phosphorus with serum calcium 9.2 
mg/dL or lower, the odds of aggressive prostate cancer increased by 74% (OR: 1.74; 95% 
CI: 1.04-2.92). Increasing serum phosphorus substantially increased the risk of 
aggressive prostate cancer in the presence of serum calcium levels above and below the 
median. Similar effects were observed in phosphorus quartiles in the presence of low and 
high PTH and 25(OH)D. Among participants in the 4th quartile of serum phosphorus 
with PTH above 40.63 pg/mL, the odds of aggressive prostate cancer increased by 185% 
(OR: 2.85, 95% CI: 1.43-5.66). The odds of aggressive prostate cancer increased by 
141% among those in the 4th quartile of serum phosphorus with 25(OH)D concentrations 
at or above the median 21.14 ng/mL (OR: 2.41, 95% CI: 1.28-4.53). 
 There were no observed effects of PTH in the presence of low or high serum 
calcium and 25(OH)D. The odds of aggressive prostate cancer was higher among all 
quartiles of PTH in the presence of high serum phosphorus concentrations (above the 
median) with the most pronounced effect being observed in the 1st quartile of PTH in the 
presence of high serum phosphorus (OR: 2.97, 95% CI: 1.70-5.18). Among men with low 
serum phosphorus, there were no substantial associations between higher PTH and 
aggressive prostate cancer compared to men with both low PTH and low phosphorus. 
There was evidence of statistical interaction between plasma PTH and serum phosphorus 
(P=0.049). 
 In the 2nd quartile of 25(OH)D, the odds of aggressive prostate cancer increased 
among those with low serum calcium (OR: 2.02, 95% CI: 1.22-3.34). Similar results were 
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observed among men in the 4th quartile of 25(OH)D with high serum calcium (OR: 2.00, 
95% CI: 1.15-3.49). Increasing 25(OH)D with serum phosphorus levels below and above 
the median increased the odds of aggressive prostate cancer, with the strongest 
association being observed for both high 25(OH)D and high phosphorus (OR: 4.25, 95% 
CI: 2.27-7.93) though the test for interaction was not statistically significant (P=0.67). 
The odds of aggressive prostate cancer among men in the 2nd and 4th 25(OH)D quartiles 
with low PTH were increased. The most pronounced effect was observed in the 2nd 
quartile of 25(OH)D (OR: 2.45, 95% CI: 1.40-4.29). 
Table 4.12: Serum Calcium and Effect Modification by BMI, Comorbidities, or Smoking 
 BMI, comorbidities, and smoking status did not modify the association between 
median cutpoints of serum calcium and odds of aggressive prostate cancer. Additionally, 
there was no evidence of statistical interaction between median cutpoints of serum 
calcium and BMI, Charlson comorbidity index, or smoking status.  
Table 4.13-4.14: Serum Phosphorus and Effect Modification by BMI, Comorbidities, or 
Smoking 
 Among those with BMI greater than 24.9 kg/m2, clinically low serum phosphorus 
(<2.8 mg/dL) was associated with significantly decreased odds of aggressive prostate 
cancer (OR: 0.43, 95% CI: 0.25-0.74). In participants with no comorbidities, the odds of 
aggressive prostate cancer were 68% lower among those with low serum phosphorus as 
compared to those with serum phosphorus within the reference range (2.8-4.5 mg/dL) 
(OR: 0.32, 95%: 0.15-0.68). Among participants with one or more comorbidities, the 
odds of aggressive prostate cancer were 51% lower in those with low phosphorus as 
compared to those with phosphorus within the normal range (OR: 0.49, 95% CI: 0.25-
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0.95). The test for interaction between comorbidities and reference ranges of serum 
phosphorus was statistically significant (P=0.004).  
 In men with a BMI above 24.9 kg/m2, the odds of aggressive prostate cancer 
among those with phosphorus levels above the median (>3.3 mg/dL) were significantly 
higher compared to those with phosphorus levels at or below the median (≤3.3. mg/dL). 
The odds of aggressive prostate cancer among those with serum phosphorus 
concentrations above 3.3 mg/dL were significantly increased among those with no 
comorbidities (OR: 1.83, 95% CI: 1.23-2.71) and those with more than one comorbidity 
(OR: 2.26, 95% CI: 1.54-3.34). Among men with serum phosphorus above 3.3 mg/dL 
who never smoked or were former smokers, the odds of aggressive prostate cancer were 
at least two-fold. Serum phosphorus above 3.3 mg/dL was not associated with increased 
odds aggressive prostate cancer among current smokers. 
Table 4.15-4.16: Plasma PTH and Effect Modification by BMI, Comorbidities or 
Smoking 
 Within strata of BMI, comorbidities, and smoking status, the odds of aggressive 
prostate cancer among men with clinically high PTH (> 55 pg/mL) were not significantly 
different than that of those with PTH within the reference range (10-55 pg/mL). 
Similarly, within strata of BMI and smoking status, PTH levels above the median (> 
40.63 pg/mL) were not significantly associated with odds of aggressive prostate cancer. 
Among men with PTH levels above 40.63 pg/mL and one or more comorbidities, the 
odds of aggressive prostate cancer decreased by 36% (OR: 0.64; 95% CI: 0.44-0.93).  
Table 4.17: Pearson Correlations 
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 A weak positive linear association between serum calcium and serum phosphorus 
was observed (Pearson correlation: 0.20, p value: <.0001). Weak negative linear 
associations were found between serum calcium and plasma PTH (Pearson correlation: -
0.11, p value: 0.0002) and serum phosphorus and plasma PTH (Pearson correlation: -
0.04, p value: 0.0002).
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Table 4.1 Characteristics of PCaP participants by high and low aggressiveness 
 
Characteristics 
Low Aggressive 
(N =783) 
High Aggressive 
(N =405) 
 Mean (SD) Mean (SD) 
Age, years 62 (8) 64 (8) 
Body mass index, kg/m2 29.0 (5.0) 29.6 (5.9) 
Alcoholic drinks, grams/day 1.2 (3.5) 1.7 (5.2) 
Serum calcium, mg/dL 9.3 (0.4) 9.3 (0.5) 
Serum phosphorus, mg/dL 4.2 (2.4) 4.4 (2.3) 
Plasma parathyroid hormone, pg/mL 45.4 (29.0) 46.9 (31.6) 
Plasma 25-hydroxyvitamin D, ng/mL 21.6 (8.9) 21.5 (10.4) 
 N % N % 
Race     
     African American 310 39.6 219 54.1 
     European American 473 60.4 186 45.9 
Family History of Prostate Cancer     
     No affected 1st-degree relative 520 66.4 288 71.1 
     At least 1 affected 1st-degree relative 206 26.3 87 21.5 
     Don’t know 57 7.3 30 7.4 
Education     
     Graduate/professional degree 126 16.1 49 12.1 
     Some college or college graduate 291 37.2 139 34.3 
     High school grad or voc/tech school 250 31.9 111 27.4 
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     Less than high school education 116 14.8 106 26.2 
Screening History (Digital and PSA)     
     No previous screening history 64 8.2 67 16.5 
     Previous DRE only 103 13.2 84 20.7 
     Previous PSA only 28 3.6 20 4.9 
     Previous history of digital rectal exam 
and PSA 
588 75.1 234 57.8 
Smoking Status     
     Non-smoker 300 38.3 115 28.4 
     Former smoker 383 48.9 218 53.8 
     Current smoker 100 12.8 72 17.8 
NSAIDs Use     
     No 298 38.1 149 36.8 
     Yes 485 61.9 256 63.2 
Charlson Comorbidity Index     
     No comorbidities 413 52.8 189 46.7 
     1, 2, or 3 comorbidities 323 41.2 186 45.9 
     More than 3 comorbidities 47 6.0 30 7.4 
aProstate cancer aggressiveness is defined as the severity of the cancer at diagnosis based on 
combinations of the Gleason score, morphologic stage, and PSA as follows: high aggressive, 
Gleason sum ≥ 8 OR PSA > 20 ng/mL OR Gleason sum = 7 (4 +3) OR Gleason sum = 7 and stage 
T3- T4; low aggressive, Gleason sum < 7 and stage T1-T2 and PSA < 9 ng/mL 
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Table 4.2 Characteristics of PCaP participants by race 
 
Characteristics 
African Americans 
(N =529) 
European Americans 
(N =659) 
 Mean (SD) Mean (SD) 
Age, years 61 (8) 64 (8) 
Body mass index, kg/m2 29.1 (5.9) 29.2 (4.9) 
Alcoholic drinks, grams/day 1.5 (4.7) 1.2 (3.6) 
Serum calcium, mg/dL 9.3 (0.5) 9.2 (0.4) 
Serum phosphorus, mg/dL 4.3 (2.4) 4.3 (2.3) 
Plasma parathyroid hormone, pg/mL 49.2 (35.7) 43.3 (23.9) 
Plasma 25-hydroxyvitamin D, ng/mL 17.7 (7.6) 24.6 (9.6) 
 N % N % 
Prostate cancer classification     
     High aggressive 219 41.4 186 28.2 
     Low aggressive 310 58.6 473 71.8 
Family History of Prostate Cancer     
     No affected 1st-degree relative 343 64.8 465 70.6 
     At least 1 affected 1st-degree relative 140 26.5 153 23.2 
     Don’t know 46 8.7 41 6.2 
Education     
     Graduate/professional degree 32 6.1 143 21.7 
     Some college or college graduate 158 29.9 272 41.3 
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     High school grad or voc/tech school 177 33.5 184 27.9 
     Less than high school education 162 30.6 60 9.1 
Screening History (Digital and PSA)     
     No previous screening history 88 16.6 43 6.5 
     Previous DRE only 125 23.6 62 9.4 
     Previous PSA only 18 3.4 30 4.6 
     Previous history of digital rectal exam and 
PSA 
298 56.3 524 79.5 
Smoking Status     
     Non-smoker 158 29.9 257 39.0 
     Former smoker 258 48.8 343 52.1 
     Current smoker 113 21.4 59 9.0 
NSAIDs Use     
     No 232 43.9 215 32.6 
     Yes 297 56.1 444 67.4 
Charlson Comorbidity Index     
     No comorbidities 257 48.6 345 52.4 
     1, 2, or 3 comorbidities 240 45.4 269 40.8 
     More than 3 comorbidities 32 6.1 45 6.8 
aProstate cancer aggressiveness is defined as the severity of the cancer at diagnosis based on 
combinations of the Gleason score, morphologic stage, and PSA as follows: high aggressive, 
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Gleason sum ≥ 8 OR PSA > 20 ng/mL OR Gleason sum = 7 (4 +3) OR Gleason sum = 7 and 
stage T3- T4; low aggressive, Gleason sum < 7 and stage T1-T2 and PSA < 9 ng/mL 
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Table 4.3 Association between concentrations of circulating calcium, phosphorus, and PTH (quartiles) and 
aggressive prostate cancer  
  Simple Modela Adjusted Modelb 
 N, High/ 
Low 
aggressive 
cases 
OR 95% CI Ptrend OR 95% CI Ptrend 
Serum calcium 
(mg/dL) quartiles 
   0.95   0.65 
≤ 8.9 107/177 1 Ref 1  Ref 
9.0-9.2 101/216 0.75 0.53-1.06 0.74 0.51-1.06 
9.3-9.5 94/195 0.79 0.56-1.12 0.78 0.54-1.13 
> 9.5 103/195 0.82 0.58-1.17 0.75 0.51-1.09 
Serum phosphorus 
(mg/dL) quartiles 
   0.07   0.06 
≤ 2.9 58/176 1 Ref 1 Ref 
3.0-3.3 81/210 1.18 0.79-1.76 1.26 0.83-1.90 
3.4-4.1 151/206 2.27 1.57-3.29 2.36 1.60-3.48 
> 4.1 115/191 1.92 1.30-2.82 2.17 1.43-3.29 
Plasma parathyroid 
hormone (mg/dL) 
quartiles 
   0.87   0.67 
≤ 30.584 114/196 1 Ref 1 Ref 
30.585-40.63 95/195 0.85 0.61-1.21 0.97 0.68-1.39 
40.64-54.2145 98/196 0.82 0.59-1.16 0.88 0.62-1.26 
> 54.2145 98/196 0.75 0.53-1.06 0.79 0.55-1.14 
aAdjusted for age and race 
bAdditionally adjusted for BMI, alcohol intake, family history of prostate cancer, previous screening history, 
NSAIDs use, Charlson comorbidity index, smoking status, education level, plasma 25-hydroxyvitamin D, and 
mutually adjusted for circulating calcium, phosphorus, and PTH 
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Table 4.4 Association between concentrations of serum calcium and phosphorusa 
(including a fifth category of values considered abnormally high clinically) and 
aggressive prostate cancer  
  Simple Modelb Adjusted Modelc 
 N, High/ 
Low aggressive 
cases 
OR 95% CI OR 95% CI 
Serum calcium 
(mg/dL), 5 levels  
     
≤ 8.9 107/177 1 Ref 1  Ref 
9.0-9.2 101/216 0.75 0.53-1.06 0.74 0.51-1.05 
9.3-9.5 94/195 0.79 0.56-1.13 0.78 0.54-1.13 
9.6-10.2 90/184 0.77 0.53-1.10 0.71 0.48-1.04 
> 10.2 13/11 1.74 0.74-4.10 1.44 0.58-3.53 
Serum phosphorus 
(mg/dL), 5 levels  
     
≤ 2.9 58/176 1 Ref 1 Ref 
3.0-3.3 81/210 1.18 0.79-1.76 1.26 0.83-1.90 
3.4-4.1 151/206 2.27 1.57-3.29 2.36 1.60-3.49 
4.1-4.5 18/33 1.64 0.85-3.18 2.04 1.02-4.05 
> 4.5 97/158 1.98 1.33-2.95 2.20 1.43-3.39 
a PTH not included in this table because the clinically high cutpoint was similar to the fourth 
quartile cutpoint in Table 4.3 
bAdjusted for age and race 
cAdditionally adjusted for BMI, alcohol intake, family history of prostate cancer, previous 
screening history, NSAIDs use, Charlson comorbidity index, smoking status, education 
level, plasma 25-hydroxyvitamin D and PTH, and mutually adjusted for serum calcium and 
serum phosphorus 
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Table 4.5 Association between concentrations of serum calcium (quartiles) and 
aggressive prostate cancer by race using uniform cutpoints 
  Simple Modela Adjusted Modelb 
Serum calcium 
(mg/dL) quartiles 
N, High/low 
aggressive 
OR 95% CI OR 95% CI 
African Americans      
≤ 8.9 45/54 1 Ref 1 Ref 
9.0-9.2 55/81 0.84 0.50-1.42 0.77 0.43-1.37 
9.3-9.5 48/80 0.76 0.44-1.30 0.69 0.38-1.24 
> 9.5 71/95 0.96 0.58-1.60 0.82 0.47-1.45 
European 
Americans 
     
≤ 8.9 62/123 1 Ref  1 Ref 
9.0-9.2 46/135 0.68 0.43-1.08 0.69 0.42-1.11 
9.3-9.5 46/115 0.84 0.52-1.33 0.85 0.51-1.41 
> 9.5 32/100 0.68 0.41-1.13 0.55 0.31-0.96 
aAdjusted for age  
bAdditionally adjusted for BMI, alcohol intake, family history of prostate cancer, previous 
screening history, NSAIDs use, Charlson comorbidity index, smoking status, education level, 
and circulating 25-hydroxyvitamin D, phosphorus, and PTH 
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Table 4.6 Association between concentrations of serum phosphorus (quartiles) and 
aggressive prostate cancer by race using uniform cutpoints 
  Simple Modela Adjusted Modelb 
Serum phosphorus 
(mg/dL) quartiles 
N, High/low 
aggressive 
OR 95% CI OR 95% CI 
African Americans      
≤ 2.9 31/61 1 Ref 1 Ref 
3.0-3.3 45/81 1.11 0.63-1.96 1.15 0.61-2.14 
3.4-4.1 79/91 1.77 1.04-3.00 1.82 1.02-3.26 
> 4.1 64/77 1.72 0.99-2.99 1.88 1.02-3.46 
European 
Americans 
     
≤ 2.9 27/115 1 Ref 1 Ref 
3.0-3.3 36/129 1.25 0.71-2.21 1.37 0.76-2.49 
3.4-4.1 72/115 2.90 1.72-4.89 3.07 1.76-5.35 
> 4.1 51/114 2.12 1.23-3.66 2.63 1.44-4.82 
aAdjusted for age  
bAdditionally adjusted for BMI, alcohol intake, family history of prostate cancer, previous 
screening history, NSAIDs use, Charlson comorbidity index, smoking status, education level, 
and circulating 25-hydroxyvitamin D, calcium, and PTH 
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Table 4.7 Association between concentrations of plasma PTH (quartiles) and aggressive 
prostate cancer by race using uniform cutpoints 
  Simple Modela Adjusted Modelb 
PTH (pg/mL) 
quartiles 
N, 
High/low 
aggressive 
OR 95% CI OR 95% CI 
African American      
≤ 30.584 65/67 1 Ref 1 Ref  
30.585-40.63 46/65 0.70 0.42-1.17 0.92 0.52-1.61 
40.64-54.2145 45/85 0.51 0.31-0.85 0.56 0.32-0.97 
> 54.2145 63/93 0.65 0.40-1.04 0.81 0.48-1.38 
European American      
≤ 30.584 49/129 1 Ref 1 Ref 
30.585-40.63 49/130 1.05 0.66-1.69 1.15 0.70-1.91 
40.64-54.2145 53/111 1.30 0.81-2.08 1.42 0.86-2.34 
> 54.2145 35/103 0.85 0.51-1.43 0.90 0.52-1.56 
aAdjusted for age  
bAdditionally adjusted for BMI, alcohol intake, family history of prostate cancer, previous 
screening history, NSAIDs use, Charlson comorbidity index, smoking status, education level, 
and circulating 25-hydroxyvitamin D, calcium, and phosphorus 
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Table 4.8 Association between concentrations of plasma PTH and aggressive prostate cancer 
by race using race-specific cutpoints 
  Simple Modela Adjusted Modelb 
PTH (pg/mL) 
race-specific 
quartiles 
High/ 
Low 
aggressive 
cases 
OR 95% CI Ptrend OR 95% CI Ptrend 
African American    0.43   0.13 
≤ 32.49 76/77 1 Ref 1 Ref  
32.50-43.75 49/78 0.61 0.38-0.99 0.72 0.43-1.22 
43.76-56.94 44/77 0.55 0.34-0.91 0.59 0.34-1.01 
> 56.94 50/78 0.61 0.37-0.98 0.70 0.41-1.20 
European 
American 
   0.37   0.80 
≤ 29.20 61/151 1 ref 1 Ref  
29.21-38.54 56/137 0.97 0.59-1.60 1.06 0.62-1.80 
38.55-51.59 35/98 1.30 0.81-2.09 1.46 0.88-2.41 
> 51.59 34/87 0.88 0.53-1.46 0.95 0.55-1.62 
aAdjusted for age  
bAdditionally adjusted for BMI, alcohol intake, family history of prostate cancer, previous 
screening history, NSAIDs use, Charlson comorbidity index, smoking status, education level, and 
circulating 25-hydroxyvitamin D, calcium, and phosphorus 
 
 
 
 
 
 
6
0
 
Table 4.9 Association between circulating calcium, phosphorus, and PTH (clinical 
ranges, using normal as the referent group) and aggressive prostate cancer  
  Simple Modela
  
Adjusted Modelb 
Clinical cutpoints of 
serum analytesc 
High/ 
Low 
aggressive 
cases 
OR 95% CI OR 95% CI 
Serum calcium 
(mg/dL) 
     
Low (< 8.5) 11/14 1.54 0.68-3.50 1.35 0.58-3.18 
Normal (8.5-10.2) 381/758 1.00 Ref 1.00 Ref 
High (> 10.2) 13/11 2.16 0.95-4.93 1.84 0.77-4.38 
Serum phosphorus 
(mg/dL) 
     
Low (< 2.8) 25/92 0.48 0.30-0.78 0.44 0.27-0.71 
Normal (2.8-4.5) 283/533 1.00 Ref 1.00 Ref 
High (> 4.5) 97/158 1.21 0.90-1.63 1.24 0.90-1.72 
Plasma parathyroid 
hormone (pg/mL) 
     
Normal (10-55) 311/596 1.00 Ref 1.00 Ref 
High (> 55) 93/186 0.85 0.63-1.14 0.83 0.61-1.13 
aAdjusted for age and race 
bAdditionally adjusted for BMI, alcohol intake, family history of prostate cancer, previous 
screening history, NSAIDs use, Charlson comorbidity index, smoking status, education 
level, plasma 25-hydroxyvitamin D, and mutually adjusted for circulating calcium, 
phosphorus, and PTH 
cClinical cutpoints based on reference ranges established by the NIH U.S. National Library 
of Medicine  
 
 
 
6
1
 
Table 4.10 Association between circulating calcium, phosphorus, and PTH (median 
cutpoints) and aggressive prostate cancer  
  Simple Modela
  
Adjusted Modelb 
Median cutpoints of 
serum analytesc 
High/ 
Low 
aggressive 
cases 
OR 95% CI OR 95% CI 
Serum calcium 
(mg/dL) 
     
≤ 9.2 208/393 1.00 Ref 1 .00 Ref 
> 9.2 197/390 0.94 0.73-1.20 0.90 0.70-1.18 
Serum phosphorus 
(mg/dL) 
     
≤ 3.3 139/386 1.00 Ref 1 Ref 
> 3.3 266/397 1.91 1.48-2.47 2.00 1.53-2.63 
Plasma parathyroid 
hormone (pg/mL) 
     
≤ 40.63 209/391 1.00 Ref 1.00 Ref 
> 40.63 196/392 0.85 0.66-1.09 0.85 0.65-1.10 
aAdjusted for age and race 
bAdditionally adjusted for BMI, alcohol intake, family history of prostate cancer, previous 
screening history, NSAIDs use, Charlson comorbidity index, smoking status, education 
level, plasma 25-hydroxyvitamin D, and mutually adjusted for circulating calcium, serum 
phosphorus, and PTH 
cMedian cutpoints established based on the 50th percentile of low aggressive case 
distribution 
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Table 4.11 Joint effects of circulating calcium, phosphorus, PTH, and vitamin Da 
 Median Cutpointsb 
Serum calcium Serum phosphorus Plasma parathyroid 
hormone 
Plasma vitamin D 
Quartiles of 
analytes 
≤ 9.2 > 9.2 ≤ 3.3 >3.3 ≤40.63 > 40.63 ≤ 21.14 > 21.14 
Serum calcium 
(mg/dL) 
        
≤ 8.9   1.00 1.99  
(1.18-
3.34) 
1.00 1.22  
(0.71- 
2.09) 
1.00 1.14 
(0.67-
1.92) 
9.0-9.2   0.58 
(0.34-
0.97) 
1.54  
(0.95-
2.48) 
0.94 
(0.55-
1.63) 
0.76 
(0.43-
1.35) 
0.82 
(0.51-
1.33) 
0.75 
(0.44-
1.26) 
9.3-9.5   0.62 
(0.34-
1.12) 
1.41 
(0.88-
2.27) 
1.09 
(0.63-
1.88) 
0.71  
(0.39-
1.29) 
0.84 
(0.50-
1.40) 
0.84 
(0.50-
1.41) 
> 9.5   0.81 
(0.44-
1.48) 
 
1.18  
(0.75-
1.86) 
1.00  
(0.57-
1.74) 
0.73 
(0.40-
1.31) 
0.67  
(0.41-
1.11) 
1.00 
(0.59-
1.67) 
Pinteraction  0.49 0.39 0.56 
Serum 
phosphorus 
(mg/dL) 
        
≤ 2.9 1.00 1.55 
(0.81-
2.97) 
  1.00 1.61 
(0.81-
3.21) 
1.00 1.04 
(0.55-
1.95) 
3.0-3.3 1.74  1.04   1.62 1.84 1.45 1.13 
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(1.04-
2.92) 
(0.56-
1.90) 
(0.81-
3.25) 
(0.93-
3.67) 
(0.82-
2.59 
(0.61-
2.08) 
3.4-4.1 2.81  
(1.71-
4.62) 
2.53  
(1.51-
4.24) 
  4.05 
(2.12-
7.74) 
2.44 
(1.25-
4.79) 
2.03 
(1.17-
3.53) 
2.74 
(1.57-
4.81) 
> 4.1 3.41  
(1.85-
6.32) 
2.07 
(1.27-
3.37) 
  3.13 
(1.60-
6.12) 
2.85 
(1.43-
5.66) 
1.93 
(1.11-
3.37) 
2.41 
(1.28-
4.53) 
Pinteraction 0.10   0.09 0.45 
Plasma 
parathyroid 
hormone 
(pg/mL) 
        
≤ 30.584 1.00 1.52 
(0.92-
2.54) 
1.00 2.97 
(1.70-
5.18) 
  1.00 0.96 
(0.58-
1.58) 
30.585-40.63 
 
1.44 
(0.84-
2.46) 
1.09 
(0.63-
1.89) 
1.16 
(0.61-
2.21) 
2.71 
(1.53-
4.79) 
  1.07 
(0.63-
1.81) 
0.85 
(0.51-
1.44) 
40.64-54.2145 1.25 
(0.74-
2.13) 
1.05 
(0.60-
1.84) 
1.70 
(0.94-
3.08) 
1.84 
(1.02-
3.34) 
  0.75 
(0.45-
1.23) 
0.97 
(0.57-
1.65) 
> 54.2145 
 
1.27 
(0.75-
2.14) 
0.79 
(0.44-
1.41) 
1.05 
(0.57-
1.95) 
2.30 
(1.28-
4.15) 
  0.66 
(0.40-
1.07) 
0.92 
(0.52-
1.64) 
Pinteraction 0.09 0.049   0.40 
Plasma vitamin 
D (ng/mL) 
        
≤ 15.15 1.00 0.91 1.00 1.87 1.00 0.96   
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(0.54-
1.54) 
(1.05-
3.34) 
(0.55-
1.68) 
15.16-21.14 2.02 
(1.22-
3.34) 
1.67 
(0.98-
2.82) 
2.22 
(1.22-
4.07) 
3.77 
(2.08-
6.81) 
2.45 
(1.40-
4.29) 
1.46 
(0.83-
2.57) 
  
21.15-26.18 1.51 
(0.85-
2.68) 
1.26 
(0.73-
2.19) 
1.27 
(0.65-
2.50) 
3.20 
(1.71-
5.99) 
1.26 
(0.70-
2.30) 
1.60 
(0.86-
2.97) 
  
> 26.18 1.69 
(0.98-
2.93) 
2.00  
(1.15-
3.49) 
1.78 
(0.93-
3.39) 
4.25 
(2.27-
7.93) 
1.96 
(1.10-
3.49) 
1.77 
(0.95-
3.32) 
  
Pinteraction 0.74 0.67 0.22   
aAll models adjusted for age, race, BMI, alcohol intake, family history of prostate cancer, previous screening 
history, NSAIDs use, Charlson comorbidity index, smoking status, education level, and mutually adjusted for 
circulating calcium, phosphorus, PTH, and 25-hydroxyvitamin D 
bMedian cutpoints established based on the 50th percentile of low aggressive case distribution 
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 Table 4.12 Associations between median cutpoints of serum calcium and prostate 
cancer aggressiveness in strata of BMI, comorbidities, and smoking status 
Median Cutpoints of Serum Calcium (mg/dL)b 
N 
(high/low 
aggressive 
cases) 
Low Calcium 
(≤9.2) 
N 
(high/low 
aggressive 
cases) 
High Calcium 
(>9.2) 
 
 OR   OR (95% CI) Pinteraction 
BMI (kg/m2)c     0.30 
Normal  
(18.5-24.9) 
27/64 1.00 (ref) 45/79 1.33 (0.69-2.58) 
Overweight/Obese 
(≥ 25) 
177/325 1.00 (ref) 152/308 0.84 (0.62-1.12) 
Charlson 
Comorbidity Index 
    0.06 
No comorbidities 104/202 1.00 (ref) 85/211 0.77 (0.53-1.13) 
 1 comorbidities 104/191 1.00 (ref) 112/179 1.04 (0.71-1.52) 
Smoking Status     0.07 
Never smoker 67/143 1.00 (ref) 48/157 0.65 (0.40-1.06) 
Former Smoker 109/205 1.00 (ref) 109/178 1.11 (0.76-1.62) 
Current smoker 32/45 1.00 (ref) 40/55 0.97 (0.48-1.97) 
a. Adjusted for age, race, BMI (in BMI unstratified groups), alcohol consumption, family history of prostate 
cancer, previous screening history, NSAIDs use, Charlson comorbidity index (in Charlson Comorbidity Index 
unstratified groups), smoking status (in smoking unstratified groups), education level, and circulating phosphorus, 
PTH,  and 25-hydroxyvitamin D 
b. Median cutpoints established based on the 50th percentile of low aggressive case distribution 
c. BMI cutpoints established by the World Health Organization (WHO) 
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 Table 4.13 Associations between clinical ranges of serum phosphorus and prostate 
cancer aggressiveness in strata of BMI, comorbidities, and smoking status 
Clinical Ranges of Serum Phosphorus (mg/dL)b 
Low Phosphorus (≤2.8) Normal Phosphorus 
(2.8-4.5) 
High Phosphorus (>4.5)  
N 
(high/low 
aggressive 
cases) 
OR (95% 
CI) 
N 
(high/low 
aggressive 
cases) 
OR  N 
(high/low 
aggressive 
cases) 
OR (95% 
CI) 
Pinteraction 
BMI (kg/m2)c       0.97 
Normal 
(18.5-24.9) 
4/18 0.36 (0.10-
1.25) 
51/98 1.00 
(ref)  
17/27 1.27 (0.57-
2.86) 
Overweight/O
bese 
(≥ 25) 
21/73 0.43 (0.25-
0.74) 
229/430 1.00 
(ref) 
79/130 1.32 (0.91-
1.89) 
Charlson 
Comorbidity 
Index 
      0.004 
No 
comorbidities 
10/42 0.32 (0.15-
0.68) 
141/273 1.00 
(ref) 
38/98 0.66 (0.40-
1.07) 
 1 
comorbidities 
15/50 0.49 (0.25-
0.95) 
142/260 1.00 
(ref) 
59/60 2.34 (1.46-
3.76) 
Smoking 
Status 
      0.14 
Never smoker 11/27 0.96 (0.41-
2.27) 
75/211 1.00 
(ref) 
29/62 1.61 (0.88-
2.94) 
Former 
Smoker 
10/55 0.25 (0.12-
0.53) 
157/252 1.00 
(ref) 
51/76 1.15 (0.72-
1.84) 
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Current 
smoker 
4/10 0.71 (0.17-
2.90) 
51/70 1.00 
(ref) 
17/20 1.16 (0.49-
2.79) 
a. Adjusted for age, race, BMI (in BMI unstratified groups), alcohol consumption, family history of prostate 
cancer, previous screening history, NSAIDs use, Charlson comorbidity index (in Charlson Comorbidity Index 
unstratified groups), smoking status (in smoking unstratified groups), education level, and circulating calcium, 
PTH, and 25-hydroxyvitamin D 
b. Clinical cutpoints based on reference ranges established by the NIH U.S. National Library of Medicine  
c. BMI cutpoints established by the World Health Organization (WHO) 
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 Table 4.14 Associations between serum phosphorus and prostate cancer 
aggressiveness in strata of BMI, comorbidities, and smoking status 
Median Cutpoint of Serum Phosphorus (mg/dL)b  
Low Phosphorus (≤3.3) High Phosphorus (>3.3)  
N 
(high/low 
aggressive 
cases) 
OR N 
(high/low 
aggressive 
cases) 
OR (95% CI) Pinteraction 
BMI (kg/m2)c     0.71 
Normal 
(18.5-24.9) 
24/67 1.00 (ref) 48/76 1.85 (0.95-3.63) 
Overweight/Obese 
(≥ 25) 
114/316 1.00 (ref) 215/317 2.12 (1.57-2.88) 
Charlson 
Comorbidity 
Index 
    0.22 
No comorbidities 68/195 1.00 (ref) 121/218 1.83 (1.23-2.71) 
 1 comorbidities 71/191 1.00 (ref) 145/179 2.26 (1.54-3.34) 
Smoking Status     0.42 
Never smoker 36/151 1.00 (ref) 79/149 2.64 (1.57-4.43) 
Former Smoker 78/193 1.00 (ref) 140/190 2.02 (1.38-2.97) 
Current smoker 25/42 1.00 (ref) 47/58 1.10 (0.53-2.27) 
a. Adjusted for age, race, BMI (in BMI unstratified groups), alcohol consumption, family history of prostate 
cancer, previous screening history, NSAIDs use, Charlson comorbidity index (in Charlson Comorbidity Index 
unstratified groups), smoking status (in smoking unstratified groups), education level, and circulating calcium, 
PTH, and 25-hydroxyvitamin D 
b. Median cutpoints established based on the 50th percentile of low aggressive case distribution 
c. BMI cutpoints established by the World Health Organization (WHO) 
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Table 4.15 Associations between clinical ranges of plasma PTH and prostate cancer aggressiveness in 
strata of BMI, comorbidities, and smoking status 
 Clinical Ranges of Plasma PTH (pg/mL)b  
Normal PTH (10-55) High PTH (> 55)  
N 
(high/low 
aggressive 
cases) 
OR N 
(high/low 
aggressive 
cases) 
OR (95% CI)b Pinteraction 
BMI (kg/m2)c     0.85 
Normal 
(18.5-24.9) 
57/112 1.00 (ref) 14/30 0.79 (0.35-1.79) 
Overweight/Obese 
(≥ 25) 
252/477 1.00 (ref) 77/156 0.81 (0.58-1.14) 
Charlson 
Comorbidity Index 
    0.92 
No comorbidities 148/320 1.00 (ref) 41/93 0.80 (0.51-1.27) 
 1 comorbidities 163/276 1.00 (ref) 52/93 0.82 (0.54-1.26) 
Smoking Status     0.72 
Never smoker 92/230 1.00 (ref) 23/70 0.76 (0.42-1.39) 
Former Smoker 161/283 1.00 (ref) 56/99 0.80 (0.52-1.21) 
Current smoker 58/83 1.00 (ref) 14/17 1.04 (0.43-2.54) 
a. Adjusted for age, race, BMI (in BMI unstratified groups), alcohol consumption, family history of prostate 
cancer, previous screening history, NSAIDs use, Charlson comorbidity index (in Charlson Comorbidity Index 
unstratified groups), smoking status (in smoking unstratified groups), education level, and circulating calcium, 
PTH, and 25-hydroxyvitamin D 
b. Clinical cutpoints based on reference ranges established by the NIH U.S. National Library of Medicine  
c. BMI cutpoints established by the World Health Organization (WHO) 
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Table 4.16 Associations between median cutpoints of plasma PTH and prostate cancer aggressiveness in 
strata of BMI, comorbidities, and smoking status 
 Median Cutpoints of Plasma PTH (pg/mL)b  
Low PTH (≤40.63) High PTH (>40.63)  
N 
(high/low 
aggressive 
cases) 
OR N 
(high/low 
aggressive 
cases) 
OR (95% CI)b Pinteraction 
BMI (kg/m2)c     0.65 
Normal 
(18.5-24.9) 
42/77 1.00 (ref) 30/66 0.82 (0.43-1.57) 
Overweight/Obese 
(≥ 25) 
165/308 1.00 (ref) 164/325 0.86 (0.64-1.15) 
Charlson 
Comorbidity Index 
    0.03 
No comorbidities 89/216 1.00 (ref) 100/197 1.12 (0.77-1.63) 
 1 comorbidities 120/175 1.00 (ref) 96/195 0.64 (0.44-0.93) 
Smoking Status     0.99 
Never smoker 60/152 1.00 (ref) 55/148 0.88 (0.54-1.44) 
Former Smoker 108/185 1.00 (ref) 110/198 0.86 (0.60-1.25) 
Current smoker 41/54 1.00 (ref) 31/46 0.77 (0.38-1.55) 
a. Adjusted for age, race, BMI (in BMI unstratified groups), alcohol consumption, family history of prostate 
cancer, previous screening history, NSAIDs use, Charlson comorbidity index (in Charlson Comorbidity Index 
unstratified groups), smoking status (in smoking unstratified groups), education level, and circulating calcium, 
phosphorus, and 25-hydroxyvitamin D 
b. Median cutpoints established based on the 50th percentile of low aggressive case distribution 
c. BMI cutpoints established by the World Health Organization (WHO) 
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Table 4.17 Pearson Correlations between circulating calcium, 
phosphorus, and PTH 
Pearson Correlation 
 Serum phosphorus Plasma PTH 
Serum calcium 0.20 
(<.0001) 
-0.11  
(.0002) 
Serum phosphorus  -0.04 
(0.0002) 
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CHAPTER 5 
DISCUSSION 
Summary and Significance of Results 
This study examined the association between circulating calcium, phosphorus, 
and PTH and the odds of aggressive prostate cancer using data from PCaP, a racially 
diverse case-only study of prostate cancer in North Carolina and Louisiana. Exposure 
variables were categorized using various cutpoints: 1) quartiles using uniform cutpoints 
determined by distributions among low aggressive cases, with or without a “clinically 
high” fifth category for calcium and phosphorus, 2) quartiles using race-specific cutpoints 
according to distribution among low aggressive cases by race,  3) clinical reference 
ranges established by the U.S National Library of Medicine, and 4) high and low 
categories based on median distribution of exposures among low aggressive cases.  
 In this study, serum calcium was associated with a modestly decreased odds of 
aggressive prostate cancer. Among the few studies that have examined the association 
between serum calcium and aggressive prostate cancer, results were inconclusive. 
Brandstedt et al. (2016) reported no association and Van Hemeljrick et al. (2013) found a 
weak positive, non-statistically significant association between serum calcium and 
aggressive prostate cancer. While our study consisted of relatively similar distributions of  
EA and AA men, previous studies were predominately comprised of European men. 
Additionally, quartile cutpoints for serum calcium in both previous studies were higher 
 
73 
than quartile cutpoints in the present study. Furthermore, both previous studies used pre-
diagnostic serum concentrations, and Van Hemeljrick et al. (2013) reported that serum 
measurements were taken 8 years prior to prostate cancer diagnosis. In the present study, 
serum measurements were fasting and taken within four months after diagnosis. Thus, 
differences in timing of blood collection, populations studied, and other study design 
differences may explain the differences in results between our study and the afore-
mentioned previous studies.  
Our study found that the odds of aggressive prostate cancer increased among men 
in the clinically low and high serum calcium categories as compared to those in the 
normal calcium range. Sample sizes among these lower and upper categories were 
relatively small, which could potentially explain why this result differed from the main 
effects analyses for serum calcium. Results of two previous studies were comparable with 
ours, though the primary outcome of these studies was total prostate cancer rather than 
aggressive prostate cancer (Jackson et al., 2015; Skinner and Schwartz, 2008). The study 
conducted by Skinner and Schwartz (2008) consisted of only 85 incident cases of prostate 
cancer, and serum samples were, on average, collected 9.9 years prior to prostate cancer 
diagnosis. The Jackson et al. (2015) study was conducted in Jamaica, and was more 
similar to ours because post-diagnostic serum concentrations were used, though they 
were non-fasting. 
Evidence generally suggests that high calcium intake increases the risk of prostate 
cancer (Rahmati et al., 2018; Aune et al., 2015), but it is difficult to disentangle whether 
these effects are a result of dietary calcium specifically or rather a marker of a diet high 
in calcium-rich dairy products which may be associated with other risk factors such as 
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saturated fat intake or obesity (Wilson et al., 2015). Moreover, serum calcium is not an 
adequate marker of dietary calcium. Serum calcium is tightly regulated, which may 
explain the conflicting, weak to modest associations observed. However, it is biologically 
plausible for serum calcium to be implicated in the progression of prostate cancer. 
Results from previous studies suggest that normal and cancerous prostate cells express 
the CaSR, though expression is higher among metastatic prostate cancer tissues (Feng et 
al., 2014). Additionally, CaSR has been associated with increased risk of fatal prostate 
cancer (Ahearn et al., 2016). Calcium is released into serum during bone remodeling, and 
it is possible that during this process, elevated serum calcium stimulates expression of the 
CaSR in tumor cells (Feng et al., 2014; Ahearn et al., 2016). 
Results from stratified analyses suggest that overweight/obesity status modified 
the association between serum calcium and aggressive prostate cancer, though the 
interaction was not statistically significant. Similar to our findings, Halthur et al. (2009) 
reported decreased risk of total prostate cancer for high serum calcium among those who 
had a BMI above 25 kg/m2. It is suggested that obesity hinders the metabolism of vitamin 
D (Lagunova et al., 2009), a calcium regulating hormone that has been postulated to 
decrease the risk of prostate cancer progression, though recent studies have produced 
inconsistent results (Murphy et al., 2013; Gao et al., 2018).  
Across various categorization approaches, higher serum phosphorus was 
significantly associated with increased odds of aggressive prostate cancer, while men 
with clinically low serum phosphorus had decreased odds compared to men in the 
clinically normal range. In a study examining the association between risk of prostate 
cancer and phosphorus intake, Wilson et al. (2015) found that high dietary phosphorus 
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was independently associated with an increased risk of prostate cancer. High serum 
phosphorus could be indicative of a diet high in phosphorus, which is commonly found in 
dairy products and processed foods. However, there is suggestion of only a weak to 
modest correlation between dietary phosphorus intake and serum phosphorus in the 
general population without renal disease (de Boer, Rue, & Kestenbaum, 2009; Gutiérrez 
et al., 2012). Due to increased availability and use of phosphate in food additives, it is 
difficult to adequately measure dietary phosphorus intake using conventional dietary 
assessment methods (Calvo et al., 2014). Since it is suggested that these assessment 
methods underestimate dietary phosphorus intake, it could also be hypothesized that this 
underestimation attenuates the true associations between serum phosphorus and dietary 
phosphorus (de Boer, Rue, & Kestenbaum, 2009). Thus, utilizing serum concentrations, 
as was done in our study, may be a better indicator of phosphorus exposure or status than 
dietary intake data. 
Comorbidities and smoking status modified the association between serum 
phosphorus and aggressive prostate cancer. The odds of aggressive prostate cancer were 
significantly increased among men with clinically high phosphorus and one or more 
comorbidities, while a modest decreased risk for clinically high serum phosphorus was 
observed among those with no comorbidities (pinteraction=0.004). Research suggests that 
men with a higher number of comorbidities have poorer prostate cancer prognosis, which 
could be attributed to the cancer itself or competing risks (Edwards et al., 2014; Rajan et 
al., 2017). Using the median cutpoint serum phosphorus variable, the odds of aggressive 
prostate cancer were significantly increased among men with high serum phosphorus 
who were never smokers or former smokers, while there was no association with high 
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serum phosphorus among current smokers. Current smokers tend to have a higher risk of 
total and aggressive prostate cancer (Huncharek, 2010; Ho et al., 2014). Perhaps high 
serum phosphorus does not substantially increase the odds of aggressive prostate cancer 
beyond that of smoking, which could explain why there was no significantly increased 
odds in this group of men.  
Elevated serum phosphorus leads to release of PTH, which has been found to 
promote progression of prostate tumor cells (Ritchie et al., 1997). Additionally, PTH 
related proteins (PTH-rp), though fundamentally different from PTH, are expressed in 
approximately 90% of localized prostate cancer cases (Bryden et al., 2002). PTH and 
PTH-rp share a common receptor, which is highly expressed in prostate cancer bone 
metastasis (Bryden et al., 2002). A recent study among Korean men reported no 
difference in serum PTH levels for men with low (7) or high (>8) Gleason grade 
prostate cancer, though men with prostate cancer had higher PTH levels compared to men 
with benign prostatic hyperplasia. They also observed substantially lower PTH levels 
after radical prostectomy (Kim et al., 2020). In the present study, in both the total 
population and race specific quartiles, PTH was non-significantly associated with a slight 
decreased odds of aggressive prostate cancer. This finding is consistent with that of the 
study conducted by Brandstedt and colleagues (2016). The biological pathways behind 
these findings are inconclusive. There was evidence of interaction and effect modification 
between PTH and number of comorbidities. The odds of aggressive prostate cancer 
among men with high PTH and one or more comorbidities were significantly decreased. 
Since PTH is a clinical marker of other diseases, this result could be the effect of 
competing risks or poor health.  
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In the joint effects analysis, across categories of low and high serum calcium, 
PTH, and 25(OH)D, high serum phosphorus was consistently associated with increased 
odds of aggressive prostate cancer, with the exception that increasing serum calcium 
appeared to attenuate the effect of high serum phosphorus on the odds of aggressive 
prostate cancer though the interaction was not statistically significant. There was 
evidence of statistical interaction between PTH and serum phosphorus, wherein the odds 
of aggressive prostate cancer were significantly increased across PTH quartiles with 
phosphorus above the median. These results are notably different from the main effects 
analysis for PTH, which further suggests that serum phosphorus is the driver for 
increased odds of aggressive prostate cancer in this study.  
Similar effects were observed for quartiles of 25(OH)D and phosphorus with 
increasing odds observed in all quartiles of 25(OH)D among those with high phosphorus 
compared to the joint low 25(OH)D-low phosphorus referent group. However, among 
men with low calcium, low phosphorus, or low PTH, the 2nd quartile of 25(OH)D was 
significantly associated with increased odds of aggressive prostate cancer compared to 
men in the lowest category of each. These may be spurious associations given the number 
of comparisons in this study. The relationship between 25(OH)D and aggressive prostate 
cancer is mixed. Several epidemiologic studies have suggested that high 25(OH)D levels 
may protect against aggressive prostate cancer (Gilbert et al., 2012; Nelson et al., 2016). 
However, in a previous study published from our dataset, Steck et al. (2015) found that 
25(OH)D was positively associated with odds of aggressive prostate cancer among AA 
men, and calcium intake modified this association. 
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Strengths and Limitations 
Our study benefited from several strengths. Participants were recruited into the 
study using a randomized recruitment procedure to allow for comparable enrollment rates 
of EA and AA men. Though AA men have an increased risk of total and aggressive 
prostate cancer, they are historically underrepresented in research studies. Additionally, 
because circulating calcium, phosphorus, PTH, and vitamin D are homeostatically 
related, they were mutually adjusted for one another.  
 Despite its strengths, the study was not without limitations. This was a case-only 
study, so comparison to a set of healthy controls was not feasible. Due to the racial 
composition of PCaP, the generalizability of the results of this study may only be 
applicable to EA and AA men. The biomarkers obtained from PCaP were taken post-
diagnosis, so it is difficult to determine if high serum phosphorus preceded or is an effect 
of aggressive prostate cancer. Sufficient data on demographic, clinical, and lifestyle 
factors were available to adjust for potential confounders, but due to the observational 
design of the study, residual confounding remains a possibility. Though the study 
consisted of 1,188 men, results from stratified analysis were limited in statistical power 
given the small sample sizes within strata. Another limitation is that we were not able to 
adjust for renal disease, which could impact circulating calcium, phosphorus, and PTH 
concentrations. Finally, blood samples were taken only once, and circulating 
concentrations could fluctuate throughout the day or from day to day.  
Recommendations for Future Research 
This study found statistically significant associations between serum phosphorus 
and the odds of aggressive prostate cancer. To our knowledge, this is the first study that 
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has examined the role of serum phosphorus in prostate cancer. Due to this, it is difficult 
to compare our findings to others. Further studies examining the role of serum 
phosphorus and aggressive prostate cancer should be conducted to confirm the results in 
the present study. Specifically, a prospective study would be best to determine if high 
serum phosphorus is a pre-diagnostic marker of aggressive prostate cancer or a result of 
aggressive prostate cancer. Since the evidence on whether serum phosphorus is an 
adequate marker of dietary phosphorus is limited, future studies could examine if similar 
effects are observed among dietary phosphorus and serum phosphorus in the same 
sample. Additionally, studies thoroughly examining factors that influence serum 
phosphorus levels in the general population are recommended.  
 Inconsistencies on the associations between aggressive prostate cancer and serum 
calcium persist. Though findings from previous studies suggest a positive association 
between PTH and metastatic prostate cancer, findings from the present study and the 
study conducted by Brandstedt et al. (2016) suggest a slight, non-significant inverse 
association between PTH and aggressive prostate cancer. The roles of PTH and serum 
calcium in aggressive prostate cancer remain unclear, and future studies should 
thoroughly examine the independent effects of these biomarkers on prostate cancer 
progression. If it is confirmed that circulating calcium, phosphorus, and PTH influence 
the progression of prostate cancer, there could be implications for incorporating them into 
strategies used to help guide clinical decisions.  
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